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PERTUSSIS: CLINICAL COURSE  
 
ertussis or whooping cough, first described in the 16th century (79), is 
caused by the gram-negative bacterium Bordetella pertussis, a strictly 
human pathogen that was first isolated in 1906 by Borduet and Gengou (16). In 
the 20th century pertussis was one of the most common childhood diseases until 
mass vaccination was introduced in the 1950s to 1960s. Before the introduction 
of vaccination almost every child contracted pertussis. The disease is most 
severe in neonates and children that are younger than 1 year. In The 
Netherlands mortality due to pertussis was 1.80/100,000 in the early 1950s 
(25).  
After a 7-10 days incubation period the onset of the disease is characterized by 
symptoms of a common cold; rhinnorrhea, malaise, low grade fever and 
anorexia. This catarrhal stage is followed after 1–2 weeks by the paroxysmal 
stage, the stage, in which the typical whooping paroxysms occur. These are 
characterized by series of repetitive coughs followed by an inspiratory gasp. 
Mucus production is common and is partially responsible for the restriction of the 
airways. The paroxysms are frequently terminated by vomiting and exhaustion, 
and especially neonates might suffer from hypoxemia. After 2–4 weeks the 
frequency and duration of the paroxysms diminish in the convalescent stage, 
which lasts several weeks to months. In this period secondary complications 
most often occur, including mainly secondary bacterial infections of the upper 
and lower respiratory tract and incidentally seizures or encephalopathy. These 
secondary complications are often the actual cause of death (73;95).  
Treatment is mainly supportive. Antibiotic treatment with erythromycin is only 
useful when started within three weeks after onset, because after this period the 
bacterium is cleared from the nasopharynx, and it is presumed that the 
remaining symptoms are caused by the secreted toxins. However, although 
erythromycin may have little effect on the clinical symptoms, it enhances the 
clearance of the bacterium and limits spread of the disease (99). Erythromycin 
prophylaxis is therefore recommended for children that are more at risk for 
complications of pertussis and for adults with pertussis, who may infect 
vulnerable children (40).  
P 
 12
VACCINATION AND EPIDEMIOLOGY 
 
In the Netherlands a whole cell vaccine (WCV) was introduced in 1953. This 
pertussis vaccine was combined with vaccines against diphtheria, tetanus and 
polio (DTPP). Children were vaccinated at the age of 3, 4, 5 and 12 months. 
Mass vaccination very effectively reduced the number of pertussis cases and a 
10-fold decrease in pertussis mortality was attained in The Netherlands in the 
late 1950s (25;148).  
Changes in the surveillance of pertussis affected the number of cases reported. 
In 1976 notification of pertussis was made obligatory by law, which resulted in 
an increased number of notifications, while in 1988 the introduction of a stricter 
case definition, including clinical symptoms and laboratory confirmation, led to a 
decline in notifications. Further, methods for laboratory confirmation of 
whooping cough, such as culture, PCR and serology, varied over the years. In 
1988 two-point serology and in 1997 one-point serology and positive PCR were 
officially introduced as diagnostics (32;97;98). As a result of the introduction of 
new diagnostic methods it became clear that pertussis was highly 
underdiagnosed in adolescents and adults. Although pertussis is most severe in 
children, it is now also recognized as an adult disease (17;64;122;132). For 
example, 13-31% of adults, who were coughing more than 1 week were shown 
to be infected with B. pertussis (122;132;160). Infected adults represent a 
reservoir for transmission to susceptible (unimmunized) children (10;78;160).  
Despite a high vaccination coverage pertussis re-emerged in The Netherlands, 
with epidemic outbreaks every 3-5 years in the last two decades. In 1996 a 
pertussis epidemic was observed with a 5-fold increase relative to the previous 
three years (Fig. 1). The incidence remained high since and epidemics also 
occurred in 1999 and in 2001 (33;34)(personal communication, H de Melker and 
S de Greeff). Pertussis has also re-emerged in other countries with highly 
vaccinated populations, such as Canada, The United States, Australia and Poland 
(3;8;36;58;59). In all these countries WCVs were introduced in the 1940s to 
1960s, which were very effective in reducing the pertussis incidence. However, 
in the 1970s negative publicity about an association between WCVs and mild 
and severe side effects adversely affected vaccine uptake. In The United 
1   Introduction 
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Kingdom the vaccine coverage dropped to 30% (86). In Sweden pertussis 
vaccination was discontinued in 1979, while in The Netherlands vaccine potency 
was decreased. As a consequence the pertussis incidence increased in these 
countries. This led to a recovery of vaccine coverage in The United Kingdom and 
an increase in vaccine potency to previous levels in The Netherlands 
(31;86;116).  
 
Fig. 1. Pertussis notifications per month in the period 1989-2001. Notifications are 
corrected for the first day of illness. 
 
WCVs cause swelling and redness at the site of injection and fever (104;138). 
Rarely encephalitis and seizures have been reported (14;85). Although it is now 
clear that there is no evidence for neurological site effects of WCVs, the negative 
publicity about the safety of the WCVs initiated the development of acellular 
pertussis vaccines (ACVs)(46;55). These ACVs comprise several purified and 
detoxified B. pertussis antigens, including pertussis toxin (Ptx)(135;136), 
filamentous hemagglutinin (FHA)(68;123), pertactin (Prn)(21) and fimbriae 
(Fim2 and Fim3)(89;109) in various combinations (reviewed in (111)). These 
vaccines were less reactogenic and showed vaccine efficacies between 58% and 
97%, dependent on the vaccine and diagnostic criteria used (reviewed in (121)). 
In The Netherlands the WCV from the 1950s is still used nowadays. 
In The Netherlands the rise in pertussis incidence in 1996 was mainly observed 
in children from 1-4 and 5-9 years old (33;34). To reduce the morbidity in 
neonates the vaccination schedule was adapted in 1999. The DTPP vaccination 
schedule was changed from 3, 4, 5 and 12 months to 2, 3, 4 and 11 months. 
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Further, in 2001 a booster vaccination with an ACV was introduced for 4-year-
old children to reduce disease burden in 5-9 year old children. 
 
VIRULENCE FACTORS OF B. PERTUSSIS 
 
B. pertussis enters the airways of the host via aerosol droplets, spread by 
infected individuals (141). The expression of most virulence factors, necessary 
for colonization of susceptibles, is regulated by the BvgAS (Bordetella virulence 
genes) system, comprising the genes coding for BvgA, BvgS and BvgR (reviewed 
in (27;83)). This system mediates the transition between a Bvg+ and Bvg- phase 
in reaction to environmental stimuli, such as temperature, nicotinic acid and 
SO4
2- concentration. BvgS is a transmembrane protein with a periplasmic and 
cytosol component, which senses the environment and is phosphorylated under 
Bvg+ conditions. The transfer of a phosphate group from BvgS to BvgA allows 
the latter to activate the promoters of virulence-activated genes (vag’s). Further 
BvgR is also activated by BvgA, which downregulates the expression of virulence 
repressed genes (vrg´s)(84). The Bvg- phase, when the expression of the vag´s 
is downregulated and vrg´s are expressed, has been suggested to be important 
for survival of the animal pathogen Bordetella bronchiseptica outside its host 
(81). Since B. pertussis is a strictly human pathogen with no known 
environmental niche, the function of this system in B. pertussis is unknown and 
it might be an evolutionary remnant. However, recently a third phase, an 
intermediate phase (Bvgi), has been identified (28;38). In the Bvgi phase some 
Bvg+ phase genes and specific Bvgi phase genes are expressed. Although the 
exact function of the Bvgi phase is unknown, this phase might be important for 
colonization of the nasopharynx, where conditions may be intermediate between 
those inducing the Bvg- and Bvg+ phase. 
Bordetella virulence factors can be divided in adhesins and toxins. The first step 
in pathogenesis, colonization of the upper respiratory tract, requires specific 
adhesins, such as FHA (29;142), Prn (20), Fim2 and Fim3 (51;52;89), tracheal 
colonization factor (TcfA)(48), Bordetella resistance to killing (BrkA) (45) and 
Vag8 (47)(Fig. 2), while the production of toxins, i.e. Ptx (12;77;94), tracheal 
cytotoxin (TCT)(53) and adenylate cyclase hemolysin (Ac-Hly)(72) is important 
1   Introduction 
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for survival in the host and transmission to susceptibles. Kinetic studies showed 
indeed that adhesins are expressed first, followed by the expression of toxins 
(70;71). In the following paragraphs I will describe the importance of Prn, TcfA 
and Ptx in pathogenesis in greater detail, because these three proteins play an 
important role in this thesis.  
 
Pertactin 
Prn or P.69, 
referring to its 
apparent molecular 
mass of 69 kDa on a 
SDS gel, is a 
protein, which 
belongs to the group 
of autotransporter 
proteins (62). This is 
a family of surface-
associated proteins 
that direct their own 
export to the outer 
membrane, where the C-terminal end undergoes proteolytic processing. 
Prn contains a RGD sequence, a tripeptide motif that binds to various 
mammalian adhesion proteins, such as vitronectin, vibronectin and fibrinogen 
(66). Via this RGD binding site Prn is thought to play a role in adherence to host 
receptors, although the specific receptor for Prn is unknown. Prn plays a role in 
attachment to CHO cells and HeLa cells (43;75). Roberts et al. showed that Prn 
participated in the attachment to a laryngeal epithelial cell line, while Van den 
Berg et al. found no difference in adhesion of a Prn-wt and Prn-ko strain to a 
laryngeal and bronchial epithelial cell line. (113;147). Further, Roberts et al. 
were not able to detect differences in colonization of mice by a Prn-wt and Prn-
ko strain (113).  
Several studies have shown that Prn is important for immunity against pertussis. 
Prn contains two repeat regions, comprising GGxxP and PQP repeats, which both 
Fig. 2. Virulence factors of Bordetella pertussis (From Alison 
Weiss, ASM News 1997) 
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have been identified as B-cell epitopes (21;69). These repeats elicited antibody 
responses in humans and mice (69). Further, epidemiological studies have 
shown a correlation between the titer of anti-Prn antibodies and clinical 
protection (23;131).  
 
Tracheal Colonization Factor 
The recently reported virulence factor, TcfA, is an adhesion factor of 64 kDa. It 
also belongs to the autotransporter family and the C-terminal part has 52% 
sequence identity with the C terminal part of Prn. TcfA also contains a RGD 
motif. Deletion of TcfA impaired the ability to colonize the trachea of mice, while 
it did not effect the survival deeper in the lungs (48). Intranasal vaccination with 
an attenuated Vibrio cholera strain, expressing TcfA, resulted in a significant 
reduction in tracheal colonization, while colonization in the lungs was not 
affected, suggesting that antibodies to TcfA may be effective in conferring 
protection (22).  
 
Pertussis Toxin 
Pertussis toxin is the major toxin of B. pertussis. It is an excreted protein of 105 
kDa, which consists of 5 subunits. Ptx consists of an A subunit, S1, which is the 
enzymatic active part and responsible for its toxicity. The B oligomer consists of 
the subunits S2, S3, S4 and S5 in a ratio of 1:1:2:1 and binds to receptors of 
eukaryotic cells and facilitates the transmembrane transport of the A subunit.  
The toxic activities of Ptx are caused by the ADP ribosylating activity of the S1 
subunit, which transfers ADP groups to G-proteins of eukaryotic cells (12). As a 
result of this, cells lose their ability to receive signals from surface receptors, 
which causes a general toxicity resulting in tissue specific effects. Ptx induces 
lymphocytosis, and hypoglyceamia in children and lymphocytosis, sensitization 
to histamine, enhancement of insulin secretion and induction of IL4 and IgE in 
animal models (93;94). Further, Ptx has been implicated in adhesion to ciliated 
cells and macrophages (112;142;161).  
Several studies have shown that Ptx is important for immunity against pertussis. 
Ptx comprises several epitopes for T-cell receptors (30;120). Epidemiological 
studies showed that antibody responses against Ptx correlate with protection 
1   Introduction 
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(23;131;137). Further, the efficacy of a monocomponent pertussis toxoid ACV 
was 76% and decreased spread of B. pertussis in a population (135;136).  
 
MOLECULAR EPIDEMIOLOGY 
 
A number of studies attempted to identify B. pertussis strains that cause 
epidemics in highly vaccinated populations, in order to explain why B. pertussis 
is able to persist in countries with a high vaccination coverage.  
In several studies pulse field gel electrophoresis (PFGE) was used to study 
changes in the B. pertussis population. Different PFGE patterns were found 
associated with isolates from the prevaccination period and isolates from the 
1990s in France and The United States (19;157). PFGE was useful to determine 
transmission patterns within communities, and in Canada and the United States 
two and one PFGE types, respectively, predominated in outbreaks (9;35). 
Further, in France, particular PFGE types were found to be linked to certain 
periods (87;157). There was, however, no association between PFGE type and 
host age, severity of infection, vaccination status and geographic distribution 
(11;19;157). Due to interlaboratory differences of this method it is not possible 
to compare the aforementioned studies to detect specific epidemic PFGE types. 
Restriction fragment length polymorphism (RFLP) based on IS1002 was used to 
study a Dutch B. pertussis population (149;150). Analysis of isolates from 
before and after the introduction of vaccination revealed large changes: The 
RFLP types from the prevaccination period disappeared and novel types 
emerged. Seventy one percent of the isolates from the 1994 Dutch pertussis 
epidemic belonged to two RFLP types, which did not predominate in the previous 
period 1991-1993. Further, isolates from different geographic regions showed 
significant differences, except 1 RFLP type that showed a worldwide distribution 
(151).  
The changes in the population structure of B. pertussis may have been caused 
by variation in proteins that are important for immunity against pertussis. Mooi 
et al. studied the Dutch B. pertussis population by investigating polymorphism in 
genes coding for surface proteins (92). Vaccine strains and clinical isolates were 
investigated for variation in Ptx and Prn. In The Netherlands vaccine strains and 
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strains from the prevaccination period produced the same variants, PtxS1B, 
PtxS1D and Prn1. However, in the period 1960-1996 divergence between clinical 
isolates and vaccine strains was observed. Ninety percent of recent isolates 
produced the non-vaccine types PtxS1A, Prn2 and Prn3, which suggests that 
vaccination has shifted the competitive balance between strains, and selected 
for variants less affected by vaccine-induced immunity (92).  
The changes in the Dutch B. pertussis population in the period 1996-2000, the 
period when the pertussis incidence was elevated, were not investigated, 
however. The goal of this thesis was to further investigate how B. pertussis 
evolved after the introduction of vaccination and to find an explanation for the 
re-emergence of B. pertussis in countries with a high vaccination coverage, in 
particular The Netherlands. 
 
 
1   Introduction 
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OUTLINE OF THIS THESIS  
 
The aim of this thesis was to explain the re-emergence of pertussis in The 
Netherlands and other countries with highly vaccinated populations. In chapter 
2 the abovementioned IS1002-based RFLP method was used to analyze strains 
from the period 1949-1996. In particular, isolates from the 1996 epidemic were 
investigated for changes in fingerprint types relative to previous years. 
Fluctuations in the genotypic diversity, based on the frequency and number of 
fingerprint types, were linked to expansion of strains that carried particular 
PtxS1 and Prn variants. In chapter 3 we extended our survey of polymorphism 
in genes coding for surface proteins. Fifteen genes, including the genes coding 
for all 5 components of the current ACVs, were investigated. The polymorphic 
genes ptxS1, ptxS3 and tcfA were used to define multi-locus sequence types 
(MLST´s), identifying 2 MLST’s that could be associated with epidemics in The 
Netherlands. In chapter 4 we investigated changes in the B. pertussis 
population in the first 20 years after the introduction of vaccination as they may 
illustrate how pathogens adapt to mass vaccination within a short time span. 
Isolates from the period 1949-1972, investigated for polymorphism in genes, 
changes in fimbrial serotype and changes in IS1002 RFLP type, showed a decline 
in frequency of vaccine type variants, while a novel variant, harboring a novel 
PtxS1 variant and fingerprint type, increased in frequency. In chapter 5 the 
effects of the variation in PtxS1 and Prn on strain fitness were investigated in a 
competition model in mice. The novel Prn and PtxS1 variants were less fit in the 
upper respiratory tract of unimmunized mice compared to the vaccine type Prn 
and PtxS1, while in the lungs the reverse was observed. In chapter 6 we 
studied polymorphism in a number of regulatory genes. We found substantial 
polymorphism in the promoter region of Ptx, ptxP, and we investigated the 
effect on production of Ptx. Finally, we found that strains carrying a novel ptxP 
variant increased strain fitness in mice by increasing the ability to colonize and 
by causing more severe disease. In the summarizing discussion in chapter 7 
the re-emergence of B. pertussis in countries with a high vaccination coverage, 
in particular The Netherlands, is discussed within the scope of molecular 
epidemiology, mathematical and animal models. 
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ABSTRACT 
 
e analyzed the population structure of B. pertussis in The Netherlands in 
five successive periods, encompassing 1949-1996, by DNA typing 
(“fingerprinting”). In a period of 10 years following the introduction of wide-
scale vaccination in 1953, a decrease in genotypic diversity (GD) was observed, 
suggesting clonal expansion of strains, which were adapted to vaccine-induced 
immunity. In subsequent periods, GD increased to prevaccination levels, 
probably reflecting a gradual adaptation of the B. pertussis population involving 
many lineages. In the 1990s, GD decreased again. This decrease coincided with 
an antigenic shift in the surface protein pertactin. No evidence was found for 
changes in DNA types or GD in 1996, when a large pertussis epidemic occurred. 
Thus gradual changes in the bacterial population previous to 1996 were probably 
the cause of the 1996 epidemic. Our results suggest that vaccination has 
selected for strains, which are adapted to a highly vaccinated population. Similar 
changes may have occurred in other countries, explaining the re-emergence of 
pertussis in vaccinated populations. 
W
2   IS1002 RFLP 
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INTRODUCTION 
 
espite the introduction of large-scale pertussis vaccination in 1953 (58) 
and a high vaccination coverage, pertussis is still an endemic disease in 
The Netherlands, with epidemic outbreaks occurring every 3-5 yrs. The year 
1996 saw an especially severe pertussis epidemic, with an incidence, which was 
5-fold higher than in previous epidemic years (33). Recent pertussis epidemics 
have also been observed in other countries such as Australia, Canada, Norway 
and The United States, notwithstanding routine vaccination (3;8;15;36). Several 
explanations have been put forward for the resurgence of pertussis in vaccinated 
populations (7;101;159). Improved surveillance, changes in case definitions and 
diagnostic techniques may result in an apparent increase in the pertussis 
incidence. However, it seems unlikely that these factors explain all cases, in 
which a dramatic rise in pertussis has been observed. Other factors, which may 
affect the incidence of pertussis include demographic changes, waning vaccine-
induced immunity, changes in vaccine quality, changes in vaccine coverage, and 
adaptation of the Bordetella pertussis population to vaccine-induced immunity. 
In previous work, we have provided evidence for the last factor, adaptation of B. 
pertussis, by showing that the Dutch B. pertussis population has undergone 
antigenic shifts in two B. pertussis surface proteins, the S1 subunit of pertussis 
toxin and pertactin (92). Pertussis toxin and pertactin variants identical to those 
found in the Dutch whole cell pertussis vaccine were found in 100% of the 
strains isolated in the 1950s, but were gradually replaced by non-vaccine types 
in later years. In the 1990s, more than 90% of the strains harbored pertussis 
toxin and pertactin variants that were different from those produced by the 
vaccine strains. DNA typing (based on the insertion sequence element IS1002) 
of Dutch strains revealed little overlap in DNA types when strains from the 
1950s were compared with those from the period 1978-1994, also providing 
evidence that shifts had occurred in the Dutch B. pertussis populations (151). 
Here we extend our previous studies by IS1002-based DNA typing of a larger 
number of strains, especially from the critical period 1950-1978, of which only a 
limited number of strains were analyzed previously. Strains from the 1996 
epidemic were also analyzed by DNA typing to determine whether novel strains 
D
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were involved. Finally, we investigated whether the antigenic shift observed for 
pertactin coincided with changes in the population structure as assessed by DNA 
typing. Our results show that the Dutch B. pertussis population has undergone 
major changes since the introduction of wide scale vaccination in 1953. One 
change occurred before 1965 and was reflected in a change in DNA types and a 
significant decrease in genotypic diversity. The second change occurred after 
1980 and involved antigenic shifts in pertactin. 
 
MATERIALS AND METHODS 
 
Strains 
B. pertussis strains were collected in the years 1949-1996. Most strains were 
sent to the RIVM by regional laboratories for serotyping or confirmation of 
identification. A potential problem for the comparison of B. pertussis populations 
from different periods, was the selection of epidemiologically related strains. 
Therefore, whenever possible, we selected those strains which, based on year of 
isolation (and if available; patient name and place of isolation) were 
epidemiologically unrelated. For strains isolated in 1988, and later, sufficient 
data were available to select epidemiologically unrelated strains. For many older 
strains (approximately 30%) either place of isolation or patient name was 
known, in addition to the date of isolation, allowing us to select strains, which 
differed in at least one of these characteristics. Sampling of epidemiologically 
related strains will tend to decrease the genotypic diversity. However, we saw 
the highest genotypic diversity in those periods, where lack of sufficient data 
about strains may have resulted in the selection of epidemiologically related 
strains. B. pertussis strains were grown on Bordet Gengou agar (DIFCO, 0048-
15-7) supplemented with 1% glycerol and 15% sheep blood, or in Verwey 
medium (156) supplemented with 200 µg/ml cyclodextrin (Sigma) at 35oC for 3 
days. 
 
IS1002-based DNA typing 
Some improvements of the previously described IS1002-based DNA typing 
method were implemented (151). The most important change was the use of 
2   IS1002 RFLP 
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Field Inversion Gel Electrophoresis (FIGE), which showed a higher resolving 
power than the classical gel electrophoresis method used previously. FIGE 
resulted in the differentiation of DNA types that were previously not resolved. B. 
pertussis chromosomal DNA was purified with the Puregene DNA isolation kit 
(D5000A, Gentra Systems Inc, Minneapolis, USA) using the protocol for Gram-
negative Bacteria as provided by the manufacturer. After purification, 1 µg of 
chromosomal DNA was digested for 2 hours, with 2 units of SmaI in a final 
volume of 200 µl, ethanol precipitated and dissolved in 10 µl sample buffer. 
Samples were applied on a 1% agarose gel (Pulse Field Certified Agarose, 
BioRad Laboratories, Hercules, CA, USA), and run on the FIGE mapper 
electrophoresis system (BioRad laboratories) for 15 hours in ½ x TBE buffer (45 
mM Tris, 45 mM borate, 1 mM EDTA, pH 8.3). The following program was used: 
Switch time ramps 0.1-0.1 seconds, linear shape, forward voltage 180 V, 
reversed voltage 120 V. As MW-marker a mixture of the 1 kb-ladder (Life 
Technologies Inc., Rockville, Maryland, USA) and the CHEF marker (BioRad 
Laboratories) was used. The marker DNA was run in at least 3 lanes. The gel 
was transferred to Hybond N+ membrane (Amersham-Pharmacia Biotech, 
Uppsala, Sweden) using standard DNA blotting techniques. The 293 base pair 
(bp) IS1002 probe used for hybridization was generated by PCR as follows: 5 µl 
of a 500 ng/µl DNA stock from strain B24 (90) was amplified with 1 unit 
SuperTaq (Sphaero-Q, Leiden, The Netherlands) in 1 x SuperTaq buffer, with 
DMSO added to a final concentration of 5%, 25 µmol of each primer, and 4 µl 
dNTP-mix containing 2,5 mM of each dNTP, in a final volume of 50 µl. PCR 
program: 1 cycle of 3 min 95oC, 35 cycles of 15 seconds 95oC, 30 seconds 60oC, 
60 sec 72oC,  and 1 cycle of 10 min 72oC. PCR was performed in a Hybaid 
Touch-Down PCR apparatus (Hybaid Limited, Ashford, Middlesex, UK). The 
following primers were used: HG1 (5’-GCCGATGCGTTCCATATA-3’), HG2 (5’-
AGCCCTTCTTGTTAACAGGG-3’). After PCR, the IS1002 probe was purified with 
the Qiaquick PCR purification kit (Qiagen, Hilden, Germany), and labeled with 
peroxidase according to the instructions provided with the “Enhanced 
Chemiluminescence Gene Detection System” (Amersham-Pharmacia Biotech, 
Uppsala, Sweden). Marker DNA was also labeled with peroxidase, and 
hybridization and detection of IS1002-containing DNA fragments and marker 
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DNA was performed according to the Amersham-Pharmacia protocol. The 
exposed films were scanned at 190 DPI (HP Scanjet IIcx/T, Hewlett Packard, 
Camas, USA). Computer-assisted analysis of the IS1002 patterns was carried 
out using the GelCompar software (Windows NT version 4.1, Applied Maths, 
Kortrijk, Belgium). To compare IS1002 patterns on different blots, the 5 bands 
of the IS1002 type dt-29 (sizes 5050 bp, 6580 bp, 8470 bp, 11100 bp, and 
15600 bp), which were shared by most DNA types, were used as internal 
standard to facilitate normalization. The IS1002-hybridizing bands in B. 
pertussis ranged in size from 2,600 to 37,800 bp. Pairwise similarities of IS1002 
DNA patterns were calculated using the Dice coefficient of similarity. Clustering 
of the isolates by similarity to give a dendrogram was carried out with UPGMA 
(unweighed pair group method with arithmetic averages). 
Genotypic diversity (GD) based on DNA typing was calculated by the equation 
GD= {n/(n-1)}(1- åxi
2), where xi is the frequency of the ith DNA type, and n is 
the number of strains (100). 
 
Statistical analysis 
The statistical significance of the difference in DNA type frequencies between 
periods was calculated by cross-tabulating frequencies by period (Fig. 2, Tables 
1 and 2) and applying the chi-square test. To comply with the conditions for the 
chi-square test (i.e. more than 80% of the cells should have an expected cell 
frequency ³ 5) the analysis was limited to the most frequent DNA types; dt-12, 
dt-29 and dt-35 for data in Table 1, and dt-10, dt-12, dt-29 and dt-35 for data 
in Table 2. For comparison of the B. pertussis populations in the periods 1949-
1954, 1965-1972, 1976-1981 and 1991-1996, the summed DNA types of the 
clades A, B and C were used (Fig. 2). The statistical significance of the difference 
in genotypic diversity (see above for definition) was estimated as follows. By 
computer simulation we randomly generated 1000 cross-tabulations similar to 
Fig. 2, and Tables 1 and 2, under the null hypothesis of no differences in 
frequency of DNA types between periods (Fig. 2 and Table 2) or prn allele 
groups (Table 1) (i.e. homogeneity existed). Under that hypothesis DNA types 
essentially occur at random in the different periods or prn groups. This can be 
simulated by a computer, by randomly shuffling the different DNA types over the 
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different periods, but changing neither the total observed number of particular 
DNA types, nor the total number of observed DNA types per period or prn group 
(the so-called "marginal totals"). We then counted the number of times, squared 
differences in genotypic diversity in the simulated tables exceeded the observed 
squared difference, and used these counts (divided by 1000) as an estimate of 
the P-value of the difference in genotypic diversity. 
 
RESULTS 
 
IS1002-based DNA typing of Dutch strains isolated in 1949-1996 
 A collection of Dutch strains, collected in the period 1949-1996 and comprising 
213 isolates, was investigated for IS1002-based restriction fragment length 
polymorphism (RFLP)(Fig. 1). The number of bands per DNA type varied 
between 4 and 8. Most DNA types (77%) contained 5 bands. Forty-five DNA 
types were observed, which were grouped in 6 families (A-F) or clades of related 
patterns with UPGMA. Clustering based on Ward or the Neighbor Joining method 
gave similar results (not shown).  
  
Temporal trends in IS1002-based DNA types 
To observe temporal trends in DNA types, strains were stratified in 5 periods 
encompassing the years 1949-1954, 1965-1972, 1976-1981, 1982-1990 and 
1991-1996, respectively (Fig. 2). Each period comprised 6 to 9 years. Since 
large-scale vaccination against pertussis was introduced in the Netherlands in 
1953 (25), period 1949-1954 can be viewed as the prevaccination period as 
strains isolated in this period would have been little affected by vaccine-induced 
immunity. 
Significant differences in DNA type frequencies were observed between the B. 
pertussis population derived from 1949-1954 and the ensuing period, 1965-
1972. These two periods share only one DNA type (dt-12), which harbors only 
5% of all isolates from both periods. All later successive periods shared at least 
3 DNA types (i.e. dt-12, dt-29 and dt-35), that represent the majority of 
isolates. 
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In period 1965-1972 one DNA type (dt-29), which was absent from the previous 
period, was found to dominate, representing 61% of all isolates. Dt-29 was also 
found in later periods, but it decreased in frequency (to 39% in period 1991-
1996). 
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The two Dutch vaccine strains belong to DNA types dt-19 and dt-43. Dt-19 was 
observed in the period 1949-1954 (frequency 8%) and in the period 1991-1996 
(frequency 3%), while dt-43 was only observed in the first period (frequency 
4%).  
Differences between the period 1949-1954 and later periods were also evident 
when the distribution of strains over the different clades was compared. Strains 
from 1949-1954 were mainly found in the clades B and E, which contained 41% 
and 34% of the isolates, respectively. In later periods these clades contained 
between 6%-39%, and 0%-1% of the strains, respectively, while most strains 
(56%-82%) were found in clade A, which harbored 4% of the strains from 
period 1949-1954. Statistical analysis based on the distribution of DNA types 
over the different populations, indicated a highly significant difference (P<0.001) 
between the B. pertussis populations from 1949-1954 and the ensuing period, 
1965-1972. In contrast, no significant differences were observed between the 
populations of 2 successive periods after the 1949-1954 period (Fig. 2). It may 
be argued that this comparison is incorrect, since the first 2 periods are 
separated by 10 years, while all subsequent periods are separated by 1 to 3 
years. However, the periods 1965-1972 and 1982-1990 are also separated by 
approximately 10 years, while the B. pertussis populations derived from these 
periods do not differ significantly with respect to DNA type distributions 
(P=0.17). 
The genotypic diversity of the strains isolated in the five periods was calculated 
(Figs. 2 and 3), and the highest (GD=0.89) and lowest (GD=0.60) diversities 
were observed, respectively, in period 1949-1954 and the succeeding period, 
1965-1972. The difference in genotypic diversity between these two periods was 
significant (P=0.016)(Fig. 2). After period 1965-1972, the genotypic diversity 
increased to, respectively, 0.69, 0.88 and 0.79 in the periods 1976-1981, 1982-
1990 and 1991-1996.  
 
Fig. 1. Dendrogram of normalized DNA types found in Dutch strains. The branching points 
of the 6 main clades are indicated with the letters A-G. The numbers refer to the 
designation of the DNA types. Clustering was performed using UPGMA. The left and right 
bars indicate the similarity coefficient and the size of DNA fragments in kilobases, 
respectively. 
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DT 49-54 65-72 76-81 82-90 91-96 clades 
38     1% (1) 
39     3% (3) 
36    5% (1)  
35  6% (1) 7% (2) 14% (3) 8% (10) 
28    5% (1) 1% (1) 
29  61% (11) 55% (16) 32% (7) 39% (47) 
30     1% (1) 
68   3% (1)   
55   7% (2)   
51     1% (1) 
53     1% (1) 
34   3% (1)  1% (1) 
79 4% (1)     
33  6% (1) 7% (2)   
A 
52     1% (1) 
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80 4% (1)     
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49     2% (2) 
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1     1% (1) 
69    5% (1)  
D 
43 4% (1)     
44 17% (4)     
45 13% (3)     
E 
48 4% (1)    1% (1) F 
N 24 18 29 22 120  
GD 0.89 0.60 0.69 0.88 0.79  
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The difference in genotypic diversity between 1976-1981 and 1982-1990 was 
marginally significant (P=0.056). P-values of other, successive, periods were not 
significant. 
Interesting differences between the five periods were also observed when the 
DNA types were grouped on the basis of the number of IS1002 copies (Fig. 3). 
In the prevaccination period, strains with 4 and 6 copies of IS1002 
predominated (frequencies, respectively 33% and 46%). In the subsequent 
period (1965-1972) all strains harbored 5 IS1002 copies, while the frequency of 
such strains was only 13% in the previous period. In later periods, strains with 
3, 4 and 6 copies were also observed, although strains with 5 copies remained 
predominant. 
Fig. 3. B. pertussis populations characterized by IS1002 copy numbers and genotypic 
diversity. Within each period the frequency distribution of strains according to their IS1002 
copy number is indicated by bars. The line shows the genotypic diversity (GD). 
  
Fig. 2. Frequency of DNA types found in the Dutch B. pertussis population in five 
successive periods. The 6 main clades (A-F) are indicated. The bar indicates the similarity 
coefficient. The boxes with the DNA types associated with the Dutch vaccine strains (dt-19 
and dt-43) have been shaded. Between parentheses, number of isolates. Abbreviation; 
DT, DNA type; N, number of strains in each period; GD, genotypic diversity. P-values for 
differences in DNA type frequencies: 49-54 versus 65-72, P<0.001; 65-72 versus 76-81, 
P=0.54; 76-81 versus 82-90, P=0.089; 82-90 versus 91-96, P=0.34. P-values for 
differences in genotypic diversity: 49-54 versus 65-72, P=0.016; 65-72 versus 76-81, 
P=0.32; 76-81 versus 82-90, P=0.056; 82-90 versus 91-96, P=0.243. 
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Association between DNA types and prn alleles 
The association between DNA types and the 3 pertactin alleles observed in the 
Dutch B. pertussis population, prn1, prn2 and prn3, was investigated for the 
period (1981-1996), in which all three types coexisted (previously, the products 
of the prn1, prn2, and prn3 alleles were referred to as P.69A, P.69B and P.69C, 
respectively)(92). The frequency distributions of the DNA types within the 3 prn 
categories were distinct (Table 1). 
For example, a high frequency (64%) of DNA type dt-29 was found in strains 
with prn3, whereas much lower frequencies were observed in strains with prn1 
and prn2 (respectively, 25% and 32%). The frequencies of dt-12 in the 3 prn 
categories were also quite different (prn1 15%, prn2 34% and prn3 8%). Some 
DNA types were uniquely associated with a particular prn allele. However, with 
the exception of the two closely related DNA types dt-9 and dt-10 (Fig. 1), which 
were uniquely associated with the prn3, the relevance of these associations 
remains to be substantiated in view of the small number of strains involved. The 
differences in DNA type frequencies between the prn1 and prn3, and prn2 and 
prn3 populations were significant (P=0.044 and P<0.001, respectively). The 
difference in DNA type frequencies between the prn1 and prn2 populations were 
not significant (P=0.83)(Table 1). 
The genotypic diversity, calculated from the DNA type data, of the prn1, prn2 
and prn3 groups were 0.91, 0.78 and 0.57, respectively (Table 1). With the 
exception of the difference between the prn1 and prn2 populations, the 
differences in genotypic diversity were highly significant (Table 1). 
 
The 1996 epidemic 
A comparison of strains isolated from the 1996 epidemic with strains isolated in 
previous periods did not reveal a significant difference in population structure 
(Table 2). In the 3 periods analyzed, 1982-1990, 1992-1995 and 1996, three 
DNA types (dt-12, dt-29 and dt-35) dominated, comprising more than 60% of 
the isolates in each period. The genotypic diversities of the B. pertussis 
population in 1992-1995 and 1996 were identical (0.79). 
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Table 1. Association between DNA types and prn allelesa. 
Frequency prn alleles† Tot DNA Type 
prn1 prn2 prn3  
7 0% (0) 2% (1) 0% (0) 1% (1) 
8 3% (1) 0% (0) 0% (0) 1% (1) 
9 0% (0) 0% (0) 4% (2) 1% (2) 
10 0% (0) 0% (0) 13% (7) 5% (7) 
12 15% (6) 34% (14) 8% (4) 18% (24) 
13 5% (2) 0% (0) 0% (0) 1% (2) 
19 0% (0) 5% (2) 0% (0) 1% (2) 
20 5% (2) 0% (0) 0% (0) 1% (2) 
23 3% (1) 0% (0) 0% (0) 1% (1) 
25 3% (1) 0% (0) 0% (0) 1% (1) 
26 0% (0) 0% (0) 2% (1) 1% (1) 
28 3% (1) 2% (1) 0% (0) 1% (2) 
29 25% (10) 32% (13) 64% (34) 43% (57) 
30 3% (1) 0% (0) 0% (0) 1% (1) 
33 3% (1) 0% (0) 0% (0) 1% (1) 
34 0% (0) 0% (0) 2% (1) 1% (1) 
35 8% (3) 12% (5) 6% (3) 8% (11) 
36 3% (1) 0% (0) 0% (0) 1% (1) 
38 0% (0) 2% (1) 0% (0) 1% (1) 
39 0% (0) 7% (3) 0% (0) 2% (3) 
45 3% (1) 0% (0) 0% (0) 1% (1) 
49 3% (1) 0% (0) 0% (0) 1% (1) 
51 3% (1) 0% (0) 0% (0) 1% (1) 
52 3% (1) 0% (0) 0% (0) 1% (1) 
53 0% (0) 2% (1) 0% (0) 1% (1) 
55 5% (2) 0% (0) 0% (0) 1% (2) 
56 5% (2) 0% (0) 0% (0) 1% (2) 
57 0% (0) 0% (0) 2% (1) 1% (1) 
68 3% (1) 0% (0) 0% (0) 1% (1) 
69 3% (1) 0% (0) 0% (0) 1% (1) 
Tot 100% (40) 100% (41) 100% (53) 100% (134) 
GD‡ 0.91 0.78 0.57 0.78 
a Isolates from the period 1981-1996 were analyzed. P-values for differences in DNA type 
frequencies: prn1 versus prn2, P=0.83; prn1 versus prn3, P=0.044; prn2 versus prn3, 
P=0.001. †Number of isolates is between parentheses. ‡Genotypic diversity. P-values for 
differences in GD: prn1 versus prn2, P=0.106; prn1 versus prn3, P<0.001; prn2 versus 
prn3, P=0.006. 
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Table 2. Frequency of DNA types found in the epidemic year 1996, and previous 
periodsa. 
DNA type Period† 
 1982-1990 1992-1995 1996 
1 0% (0) 0% (0) 1% (1) 
7 0% (0) 2% (1) 0% (0) 
8 5% (1) 0% (0) 0% (0) 
9 0% (0) 2% (1) 1% (1) 
10 0% (0) 8% (4) 9% (6) 
12 14% (3) 23% (11) 21% (15) 
13 9% (2) 0% (0) 0% (0) 
19 0% (0) 0% (0) 4% (3) 
20 0% (0) 4% (2) 0% (0) 
23 5% (1) 0% (0) 0% (0) 
25 5% (1) 0% (0) 0% (0) 
26 5% (1) 0% (0) 0% (0) 
28 5% (1) 0% (0) 1% (1) 
29 32% (7) 40% (19) 39% (27) 
30 0% (0) 2% (1) 0% (0) 
34 0% (0) 2% (1) 0% (0) 
35 14% (3) 6% (3) 10% (7) 
36 5% (1) 0% (0) 0% (0) 
38 0% (0) 0% (0) 1% (1) 
39 0% (0) 6% (3) 0% (0) 
49 0% (0) 0% (0) 3% (2) 
50 0% (0) 0% (0) 3% (2) 
51 0% (0) 0% (0) 1% (1) 
52 0% (0) 0% (0) 1% (1) 
53 0% (0) 0% (0) 1% (1) 
56 0% (0) 4% (2) 0% (0) 
57 0% (0) 0% (0) 1% (1) 
69 5% (1) 0% (0) 0% (0) 
Tot 100% (22) 100% (48) 100% (70) 
GD‡ 0.88 0.79 0.79 
a P-values for differences in DNA type frequencies: 1982-1990 versus 1992-1995, P=0.34; 
1992-1995 versus 1996, P=0.92. †Number of isolates between parentheses. ‡Genotypic 
diversity. Differences in GD were not significant (P>0.23). 
2   IS1002 RFLP 
 35
DISCUSSION 
 
Like the use of antibiotics, vaccination can impose a strong selective force on 
populations of microorganisms. Nevertheless long term, population-based, 
studies addressing the effect of vaccination are limited. In one study, some 
evidence was provided for a modest increase in the incidence of invasive disease 
by H. influenzae serotype f after introduction of H. influenzae serotype b 
vaccination (144). A second study, focused on the measles virus, provided 
evidence that vaccination has affected the population structure of the virus, and 
selected for strains, which are antigenically distinct from the vaccine strain. The 
nucleoprotein (N) and matrix (M) genes of wild-type isolates from the 
prevaccination era (before 1964) were highly related to each other and to the N 
and M genes from the measles vaccine strain. In contrast, the N and M genes of 
wild type viruses isolated between 1977 and 1989 showed genetic drift, which 
resulted in antigenic differences with the vaccine strain (117;134). Here we 
extend our previous studies (92;151) on the effect of vaccination on the 
population structure of B. pertussis. 
We analyzed temporal trends in the population structure of B. pertussis in the 
years 1949-1996 in The Netherlands. Strains were stratified in 5 periods 
encompassing the years 1949-1954, 1965-1972, 1976-1981, 1982-1990 and 
1991-1996, respectively (Fig. 2). Large-scale vaccination against pertussis was 
introduced in the Netherlands in 1953 (25), and isolates from the earliest period 
analyzed, 1949-1954, probably represent a B. pertussis population, which has 
not been significantly affected by vaccination. Differences were found between 
the populations from the five periods, reflected in the frequency of DNA types 
(Fig. 2), the number of IS1002 copies (Fig. 3), and the genotypic diversity (Figs. 
2 and 3). The most pronounced differences were observed between the 
populations from 1949-1954 and the ensuing period, 1965-1972, and it seems 
likely that these changes were driven by vaccination. However, other 
explanations for the observed changes in the population structure of B. 
pertussis, such as random genetic drift or changes in the human population 
unrelated to vaccination, cannot be excluded. 
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The decrease in genotypic diversity (from 0.89 in 1949-1954 to 0.6 in 1965-
1972, P=0.016) observed after the introduction of vaccination may have been 
caused by a decrease in the bacterial population size and/or by clonal expansion. 
Both possibilities are consistent with the effect of the introduction of vaccination, 
since the resultant increased herd immunity may (temporarily) reduce the 
circulation of the pathogen, and/or cause shifts in the relative fitness of strains. 
For example, strains that are antigenically distinct from the vaccine strains may 
be less affected by vaccine-induced immunity and expand. The observation that 
61% of the isolates from 1965-1972 belonged to a single DNA type (dt-29), 
which was not found in the previous period, is consistent with clonal expansion. 
The predominance of dt-29 decreased in subsequent periods (to 39% in 1996), 
while the genotypic diversity of the B. pertussis population increased, suggesting 
a gradual expansion of other lineages. 
In period 1965-1996 three DNA types (dt-12, dt-29 and dt-35) were 
predominant comprising between 60% and 73% of the isolates. Strain typing 
with pulsed field gel electrophoresis (PFGE) also revealed a predominance of 2-3 
PFGE types in the B. pertussis population in Canada and England (35;133). A 
single PFGE type was observed during an epidemic in the US, which occurred in 
a small rural community (9). B. pertussis is thought to be a very homogenous 
species. For example, multi-locus enzyme electrophoresis (MLE) has revealed 
only 4 electrophoretic types (96;151). In contrast, IS1002-based DNA typing 
revealed 45 DNA types for 213 isolates. Thus IS1002-based DNA typing revealed 
a much faster molecular clock than MLE, presumably due to transposition of, and 
recombination between, the IS element. A similar observation was made for 
Mycobacterium tuberculosis (128;152).  
Antigenic divergence between vaccine strains and circulating strains may be the 
underlying cause of the changes observed with DNA typing, and in fact such 
divergence has been found by us for two B. pertussis proteins, the S1 subunit of 
pertussis toxin and pertactin (92). The antigenic shifts in pertactin cannot 
explain the change in population structure observed between 1954 and 1965, 
since it occurred in the 1980s, and all strains isolated previous to 1981 produce 
a single pertactin type, which is identical to the type found in the Dutch 
pertussis vaccine. Therefore, we can discern at least two, temporally separated, 
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changes in the B. pertussis population, the first of which occurred before 1965, 
while the second, involving an antigenic shift in pertactin, occurred after 1980. It 
is not clear what adaptation caused the first shift. We have shown that the s1 
alleles found in the prevaccination era have largely been replaced by a novel 
type in the period 1978-1985, and this antigenic shift may explain the changes 
in population structure observed previous to 1965. We are currently analyzing 
s1 allele frequencies in the period 1954-1965, to substantiate this possibility. 
However, antigenic shifts in other B. pertussis antigens, such as integral outer 
membrane proteins or lipopolysaccharide, may be the underlying cause of the 
changes in the bacterial population structure previous to 1965. We have not 
been able to associate the first change with increases in mortality or morbidity in 
the years 1954-1972. This may reflect the lack of adequate surveillance in this 
period, however. Obligatory notification of pertussis was introduced in The 
Netherlands in 1976. 
The second change involved antigenic shifts in pertactin, a surface protein 
known to be protective in man and animals (54;104;114). If these shifts were 
due primarily to clonal expansion, one would expect this to be reflected in a 
decrease in genotypic diversity. The prn1 frequency drops from 100% in the 
period 1949-1972 to 85%, 80% and 13% in the periods 1976-1981, 1982-1990 
and 1991-1996, respectively (Table 3).  
 
Table 3.  Frequencies of prn alleles and genotypic diversity in different periods. 
Period prn frequencies * 
 prn1 prn2 prn3 
Genotypic  
diversity† 
1949-1954 100% (10) 0% (0) 0% (0) 0.89 
1965-1972 100% (10) 0% (0) 0% (0) 0.60 
1976-1981 85% (23) 11% (3) 4% (1) 0.69 
1982-1990 80% (16) 10% (2)  10% (2) 0.88 
1991-1996 13% (13) 36% (36) 51% (50) 0.79 
*Based on Mooi et al., 1998. Number of isolates is between parentheses. †Calculated from 
the frequency of DNA types. 
 
Thus, the largest difference in prn1 frequency (i.e. the largest increase in the 
frequencies of prn2 and prn3) is found between the last two periods and this 
difference coincides with a decrease in genotypic diversity from 0.88 in 1982-
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1990 to 0.79 in 1991-1996 (Table 3) albeit a small one, which was not 
statistically significant (P=0.243). In contrast the genotypic diversity increased 
between 1965 and 1990 (Table 3). 
Subpopulations of isolates harboring distinct prn alleles could be distinguished 
on the basis of the distribution of DNA types and genotypic diversity (Table 1). 
The lower genotypic diversity of the prn2 and prn3 groups, compared to the 
prn1 group (P-values, respectively, 0.106 and <0.001), is consistent with the 
observation that prn1 strains represent the oldest lineage (92). The prn3 group 
shows the lowest genotypic diversity, suggesting it represents a younger lineage 
than the prn2 group (P=0.006). This is also suggested by the observation that 
prn3 strains are geographically more restricted than prn2 strains (unpublished 
data). 
In 1996 there was a large and unexpected pertussis epidemic in the Netherlands 
(33). Such an epidemic may be caused by changes in the bacterial population, 
for example by the introduction (either by import or mutation) and subsequent 
clonal expansion of novel strains, which are less affected by vaccine-induced 
immunity. An epidemic may also be caused by changes in the immune status of 
the host population, for example due to waning vaccine-induced immunity or to 
a decrease in vaccine quality. A comparison of strains isolated in 1996 and 
previous years (Table 2) did not reveal major shifts in DNA types or changes in 
genotypic diversity. Thus no evidence was found for the introduction or 
expansion of particular strains. The antigenic divergence observed between 
circulating strains and vaccine strains may have gradually decreased vaccine 
efficacy, resulting in the crossing of a critical threshold in 1996.  
This study provides evidence that the Dutch B. pertussis population has adapted 
to vaccination. Similar changes may have occurred in other countries, explaining 
the re-emergence of pertussis in vaccinated populations (3;8;15;36). Our 
results predict that WCV will protect less well against recent isolates compared 
to strains from the 1950s. Preliminary studies in a mouse model have confirmed 
this prediction (unpublished data). Most pertussis vaccines are derived from 
strains isolated more than 50 years ago (151). It seems plausible that such 
vaccines may be made more effective by using contemporary strains. 
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ABSTRACT 
 
espite more than 50 years of vaccination, Bordetella pertussis has 
remained endemic in The Netherlands, causing epidemic outbreaks every 
3-5 years. Strain variation may play a role in the persistence of B. pertussis and 
was studied by sequencing 15 genes coding for surface proteins, including genes 
for all 5 components of acellular pertussis vaccines (ACVs): pertussis toxin (Ptx), 
pertactin (Prn), filamentous hemagglutinin (FHA) and fimbriae (Fim2 and Fim3). 
A low level of allelic variation was observed, suggesting a recent evolutionary 
origin of B. pertussis. In modern isolates polymorphism was observed only in 
prn, ptxS1, ptxS3 and tcfA. The ptxS1, ptxS3 and tcfA genes were used to 
categorize isolates in Multi-locus Sequence Types (MLST’s). Analysis of Dutch 
isolates from 1949-1999 revealed 5 MLST’s, which showed a highly dynamic 
temporal behavior. We observed significant changes in the MLST’s after the 
introduction of pertussis vaccination in The Netherlands. Epidemic years were 
found to be associated with expansion of MLST-4 or MLST-5. MLST-5 showed a 
remarkable expansion from 10% in 1997 to 80% in 1999. The MLST analysis 
was extended to a number of widely separated geographic regions: Australia, 
Finland, Italy, Japan and The United States. MLST-4 was found to dominate in 
Australia and Italy, while MLST-5 predominated in the United States. In Finland 
and Japan, MLST-3 and MLST-2, respectively, dominated. Thus, although each 
region showed distinctive MLST frequencies, in 4 of the 6 regions MLST-4 and 
MLST-5 were predominant. These types may represent, newly emerged, 
successful clones. The identification of highly successful clones may shed light 
on the question how B. pertussis is able to maintain itself in vaccinated 
populations. 
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INTRODUCTION 
 
espite more than 40 years of vaccination, pertussis has remained an 
endemic disease, with epidemic outbreaks occurring every 3-5 years. In 
some vaccinated populations (e.g. in Australia, Canada, The Netherlands, The 
United States) the incidence of pertussis is increasing (3;8;33;34;36;58). The 
resilience of Bordetella pertussis to vaccination may be due to its highly 
infectious nature, its relative brief stay in the host, its ability to hamper the host 
immune response, shortcomings of pertussis vaccines and strain variation. Our 
studies on strain variation have led us to suggest that the resurgence of 
pertussis may be due, in part, to the adaptation of the B. pertussis population to 
vaccination (92). The aim of this work was twofold. First, to extend these 
studies and to find markers suitable for the analysis of B. pertussis populations. 
Second, to determine the extent of polymorphism in immunologically relevant 
proteins, in particular those incorporated in acellular vaccines (ACVs). 
Recently, Multi-Locus Sequence Typing (MLST) has been introduced as a new 
approach to study the molecular epidemiology of bacterial pathogens (42;127). 
MLST is based on the well-tested principles of Multi-Locus Enzyme 
Electrophoresis (MLEE), but assigns alleles at each locus directly by nucleotide 
sequencing, rather than indirectly from electrophoretic mobilities of their gene 
products in starch gels. In contrast to many current typing methods (e.g. RFLP, 
RAPD, etc) MLST allows unambiguous interlaboratory comparisons. Importantly, 
MLST has proven to be especially suitable to study longer term and global 
epidemiology (39;44;65). 
B. pertussis is a very homogeneous species, and consequently finding 
polymorphic sites for MLST has proven to be difficult. MLEE revealed only 4 
electrophoretic types (150). Consistent with this, we found very little 
polymorphism in B. pertussis genes coding for housekeeping genes (unpublished 
data). In view of the restricted polymorphism found in B. pertussis, we 
attempted to increase the likelihood of identifying allelic variation by analysis of 
genes for surface proteins, which are subject to more intensive selective 
pressures. In previous work we showed that the S1 subunit of pertussis toxin 
(PtxS1) and pertactin (Prn) were polymorphic (19;82;88;92). PtxS1 and Prn 
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comprise 2 of the 5 B. pertussis proteins of ACVs. In this work, we investigated 
polymorphism in the remaining B. pertussis proteins, which are included in 
ACVs: the pertussis toxin subunits S2-S5 (PtxS2-S5), filamentous hemagglutinin 
(FHA), and serotype 2 and 3 fimbriae (Fim2 and Fim3). Further, we analyzed 
variation in a number of other surface-associated proteins, some of which have 
been shown to be important for immunity: two integral outer membrane 
proteins, OmpP and OmpQ (6;76), tracheal colonization factor (TcfA)(48), 
Bordetella resistance to killing protein (BrkA)(110), Vag8 (47) and Bordetella 
intermediate phase protein (BipA)(130). The polymorphic genes were used to 
characterize strains from widely separated geographic areas, providing a global 
perspective. We identified MLST's associated with epidemics, and with strains, 
which have spread globally. Analysis of these strains may reveal why B. 
pertussis is able to persist, and even cause epidemics, in highly vaccinated 
populations. 
 
MATERIAL AND METHODS 
 
Strains 
B. pertussis strains were collected from 1949 to 1999. In total 205 strains were 
investigated: 128 from The Netherlands, 27 from Finland, 10 from Italy, 9 from 
Australia, 13 from Japan and 18 from The United States. A table, detailing the 
origin of the strains, is available from the authors. Strains were grown on Bordet 
Gengou agar supplemented with 1% glycerol and 4% sheep blood at 35oC for 
three days. 
 
DNA Sequencing 
PCR amplification of chromosomal DNA was performed by adding 1 µl of DNA to 
19 µl buffer comprising 50% HotstarTaq Master mix (Qiagen, Germany), 1 µM of 
each primer, 5% or 10% dimethyl sulfoxide. 5% dimethyl sulfoxide was added 
to the PCR mix for amplification of fim2, fim3, fhaB, ompP, ompQ, ptxS1-ptxS5 
and tcfA. For bipA, brkA, prn, and vag8 10% dimethyl sulfoxide was used. 
Amplification of genes was performed in a Hybaid Omnigene incubator, using a 
specific program for each gene. The PCR fragments were purified with a 
3   MLST 
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Qiaquick PCR purification kit (Qiagen, Germany) and sequenced with the primers 
used for amplification and internal primers. The primer sequences and PCR 
programs can be obtained from the authors. Sequence reactions were performed 
with an ABI Prism Big Dye terminator reaction kit and the reactions were 
analyzed with a model 377 or 3700 ABI DNA Sequencer (Perkin-Elmer Applied 
Biosystems). For bipA, brkA, fim2, fim3, ompP, ompQ, ptxS1, ptxS2, ptxS3, 
ptxS4, ptxS5, and vag8 the complete open reading frame was sequenced. The 
fhaB gene from 13 strains was sequenced between bases 1 and 6612. This 
region codes for the secreted, processed, molecule incorporated in ACVs. 
Subsequently, sequencing of fhaB was confined to the region comprising bases 
2250-2750, which contained the single polymorphic locus identified. The tcfA 
gene from 5 strains was sequenced completely. Two polymorphic regions were 
identified between bases 1 and 945. A region comprised of bases 395-945 was 
sequenced for all strains. As polymorphism in the region of bases 1-395, 
appeared to be linked to polymorphism in region 395-945 (i.e. was non-
informative), it was sequenced for 1 out of 5 Dutch strains and for all strains 
outside The Netherlands. Previously, 2 polymorphic regions (region 1 and 2) 
were identified in prn, and essentially all polymorphism was found to be 
restricted to region 1 (92). Region 1 was sequenced for all strains, whereas 
region 2 was sequenced for 20% of the strains. 
 
RESULTS 
 
Polymorphism in B. pertussis genes coding for surface proteins 
We investigated polymorphism in 15 genes, coding for surface proteins (Table 
1). Each gene was sequenced completely for at least 5 strains, 2 strains isolated 
in the 1950s and used for the Dutch WCV, and 3 epidemiologically unrelated, 
recent, Dutch clinical isolates. The rationale behind this approach was as follows. 
We presumed that vaccination has selected for strains, which are antigenically 
distinct from the vaccine strains and hence carry different alleles for surface 
proteins. Thus, by comparing the vaccine strains with recent isolates from the 
vaccinated population, the likelihood of finding polymorphism was enhanced. 
Further, we included strain 18323 in our analysis, which represents a distinct 
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branch in the phylogenetic tree of B. pertussis (96;150). Subsequently, the 
analysis of a subset of the 15 genes, which showed polymorphism in the Dutch 
B. pertussis population after the introduction of vaccination in 1953, was  
 
Table 1. B. pertussis genes analyzed for polymorphism. 
Gene allele no of strains 
analyzed 
Frequency (N) GenBank 
Accession no 
ptxS11  205  M13223 
 ptxS1A  80% (163) AJ245366 
 ptxS1B  16% (33) AJ245367 
 ptxS1D  3% (7) AJ245368 
 ptxS1E  1% (2) AJ006151 
ptxS21  21  M13223 
ptxS31  205   
 ptxS3A  79% (161) M13223 
 ptxS3B  21% (44) AJ420987 
ptxS41  22  M13223 
ptxS51  22  M13223 
prn2  205   
 prn1  34% (69) AJ011091 
 prn2  40% (82) AJ011092 
 prn3  23% (48) AJ011093 
 prn4  0.5% (1) AJ011015 
 prn5  1.5% (3) AJ011016 
 prn6  1% (2) AJ132095 
fim21  19   
 fim2-1  84% (16) Y00527 
 fim2-2  16% (3) AJ420988 
fim31  12  X51543 
brkA1  5  U12276 
fhaB3  22   
 fhaB-1  86% (19)  M60351 J04531 
X52156 
 fhaB-2  14% (3) AJ420989 
ompP1  18  X58488 
ompQ1  5   
 ompQ1  17% (1) U16266 
 ompQ2  83% (5) AJ420990 
tcfA4  205   
 tcfA1  1% (2) U16754 
 tcfA2  78% (160) AJ009785 
 tcfA3  20% (41) AJ420991 
 tcfA4  0.5% (1) this study 
 tcfA5  0.5% (1) AJ420992 
vag81  5   
 vag8-1  17% (1) U90124 
 vag8-2  83% (5) AJ420993 
bipA1  5   
 bipA1  83% (5) P. Cotter 
 bipA2  17% (1) this study 
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extended to strains from Australia, Finland, Italy, Japan and The United States. 
No polymorphism was found in brkA, fim3, ompP, ptxS2, ptxS4, and ptxS5. 
Polymorphism was observed in bipA, fhaB, fim2, ompQ, ptxS1, ptxS3, prn, tcfA 
and vag8 (Fig. 1). Data from 2 genes, ptxS1 and prn, were mainly from previous 
studies (19;82;88;92). However, here we extended previous data by analyzing 
Japanese isolates and Dutch isolates from 1997-1999. In total 23 point 
mutations were observed in the polymorphic genes, 16 of which were non-silent. 
The silent mutations were found in ptxS3 (n=1), prn (n=4) and vag8 (n=2), 
while the non-silent mutations were found in fim2 (n=1), fhaB (n=1), ompQ 
(n=1) ptxS1 (n=4), prn (n=5), tcfA (n=3) and vag8 (n=1). In bipA a variable 
number of repeats was found (Fig. 1). Polymorphism in bipA, fim2, fhaB, ompQ 
and vag8 was restricted. Two alleles were found for each of these genes, 
resulting from polymorphism in 1 (bipA, fim2, fhaB, and ompQ) or 3 (vag8) loci 
(Fig. 1). Further, different alleles for these genes were only observed to co-exist 
in the prevaccination era in The Netherlands (fim2, fhaB), or variation was only 
observed relative to the atypical strain 18323 (bipA, ompQ, vag8). In the period 
1990-1999, only bipA1, fim2-1, fhaB1, ompQ2 and vag8-2 were found in the 
Dutch B. pertussis population. 
The genes ptxS1, ptxS3, prn, and tcfA, revealed allelic variation in recent 
isolates (i.e. from the period 1980-1999), and were selected for further analysis 
using isolates from widely separated geographic regions. Polymorphism in ptxS3 
and tcfA was not described previously. For ptxS3, 2 alleles were found, which 
differed in a single nucleotide resulting in a silent mutation (Fig. 1). Five tcfA 
alleles were found (Fig. 1). In total, 5 polymorphic loci were observed in tcfA, 
one of which consisted of a 60 bp segment flanked by 2, 15 bp, direct repeats in 
1 Genes sequenced completely. 2 prn region 1 was sequenced for all strains and region 2 for 
20% of the strains. 3 The fhaB gene from 13 strains was sequenced, between bases 1 and 
6612. This is the region that codes for the secreted, processed, molecule incorporated in 
ACVs. For the remaining strains, the region comprising bases 2250-2750 and containing 
the polymorphic locus, was sequenced. 4 The tcfA gene from 5 strains was sequenced 
completely. Subsequently, the region between bases 395 and 945 was sequenced for all 
strains. The region between bases 1 and 394 was sequenced for 1 out of 5 Dutch strains 
and all strains from outside The Netherlands. 
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  1A 
    1909           2995 
bipA1  GGC-AAC-[NNN]360-CGG-AGC-CCC-GAG-GGC-ACC-CGC-GCC-TAT-GTG-GAC-ACC-GTG-GAC 
    G   N           R   S   P   E   G   T   R   A   Y   V   D   T   V   D 
 
bipA2  ...-...-[XXX]360-...-...-...-...-...-...-...-...-...-...-...-...-...-... 
  .   .            .   .   .   .   .   .   .   .   .   .   .   .   .   . 
 
                521 
fim2-1 AGC-AGA-ACC 
             S   R   T 
fim2-2 ...-.A.-... 
             .   K   . 
 
                2493 
fhaB1  GAT-CAA-GCC 
             D   Q   A 
fhaB2  ...-..C-... 
             .   H   . 
  
              1025 
ompQ1  GAT-CTG-GAA 
             D   L   E 
ompQ2  ...-.C.-... 
             .   P   . 
 
               420   692           2607 
vag8-1 ACG-CGT-TTG-//-GTC-GTC-GGG-//-TCG-CGC-GGC  
             T   R   L     V   V   G      S   R   G 
 
vag8-2 ...-..C-...-//-...-.C.-...-//-...-..T-...  
             .   R   .      .   A   .      .   R   .  
 
                681 
ptxS3A  ATA-TGC-TGA 
             I   C 
ptxS3B  ...-..T-... 
             .   C 
 
          154        388                        451               596 
tcfA1  GAG-CTG-//-GGG-GGG-GGC-ACG-CAT-GAA-//-CCG-[NNN]25-GAT-//-GCA-TCG-GGT 
    E   L      G   G   G   T   H   E      P          D      A   S   G 
tcfA2  A..-...-//-...-...-...-...-...-...-//-...-[XXX]25-...-//-...-...-... 
    K   .      .   .   .   .   .   .      .          .      .   .   . 
tcfA3  A..-...-//-...-...-...-...-...-...-//-...-[XXX]25-...-//-...-...-.A. 
   K   .      .   .   .   .   .   .      .          .      .   .   D 
tcfA4  A..-...-//-...-...-...-...-...-...-//-...-[XXX]25-...-//-.T.-...-... 
   K   .      .   .   .   .   .   .      .          .      V   .   . 
tcfA5  A..-...-//-...-...-..G-CAC-GCA-TGA 
    K   .      .   .   .   H   A  
 
1B 
 
CTGCGCCCGGACCGGGTGGTCTGGGCCGCAATGACGAAAACTCCGAAAGTTCGCTGAATCCGGGAACTCTCGGACCTTCGCCCCGGCCGG 
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tcfA1. In the other 4 alleles, the 60 bp fragment and 1 repeat was missing, 
suggesting that a 75 bp deletion had occurred by recombination between the 
repeats. Three polymorphic sites comprised single base substitutions resulting in 
amino acid changes. The 5th polymorphic site comprised a homo-polymeric tract 
of 9 (tcfa1-4) or 10 G’s (tcfA5). The additional G in tcfA5 results in a frame shift 
and premature termination of translation. 
 
Multi-locus sequence types 
Three genes, ptxS1, ptxS3 and tcfA, were used to define MLST’s (Table 2). 
Although prn also showed polymorphism it was not used for the MLST typing 
scheme, as variation in prn is mainly due to insertion and deletion of repeat 
units, a process that is expected to occur relatively frequently, and is reversible. 
This is in contrast to the (point) mutations observed in ptxS1, ptxS3 and tcfA. In 
total 9 MLST’s could be distinguished. 
 
Temporal trends in MLST frequencies in The Netherlands 
The availability of an extensive, well-defined, strain collection allowed a detailed 
analysis of MLST frequencies in The Netherlands. To investigate temporal trends, 
strains were stratified in different periods: 1949-1952 (the prevaccination 
period), 1965-1980, 1981-1985, 1986-1990, 1991-1995, 1996-1999 (Fig. 2). 
Two MLST’s (MLST-1 and MLST-2) were observed in the prevaccination era 
comprising 45% and 55% of the population, respectively. The 2 Dutch vaccine 
strains each represent one of the two MLST’s. MLST-1 disappeared after the 
Fig. 1. Alleles of genes coding for B. pertussis surface proteins. (A). Numbers refer to the 
underlined residues. Numbering is relative to the start of the open reading frame. Dots 
indicate identity, and codons are separated by dashes. Deletions are indicated by X. In 
bipA, [NNN]360 indicates a region of 1080 bp that is absent in bipA2. This region contains 
4 repeats indicated by arrows. A fifth repeat, indicated by the long arrow, is found in both 
alleles. In tcfA1, [NNN]25 indicates a region of 75 bp, which is absent from the remaining 
alleles. The arrow below tcfA5 indicates an inserted G, which changes the reading frame 
and results in premature translational termination 2 codons downstream. (B). The 60 bp 
segment, flanked by 2 direct repeats (underlined), which is found in tcfA1. The left repeat 
is found in the alleles tcfA2-5. 
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introduction of vaccination, and was only observed again in the period 1991-
1995, when it comprised 3% of the strains analyzed. The frequency of MLST-2 
also decreased after the introduction of vaccination, dropping to 33%, 30% 
10%, 3% and 4%, respectively, in the periods 1965-1980, 1981-1985, 1986-
1990, 1991-1995 and 1996-1999. In the period 1965-1980, a novel MLST was 
found (MLST-3), initially comprising 67% of the isolates, and increasing in 
frequency to 70% and 90% in the periods 1980-1985 and 1986-1990, 
respectively. In the subsequent 2 periods, 1991-1995 and 1996-1999, the 
frequency of MLST-3 dropped to 19% and 30%, respectively. In the period 
1991-1995, two new MLST’s emerged (MLST-4 and MLST-5), which were found 
in frequencies of 39% and 37%, respectively, in the period 1991-1995 and 26% 
and 40% in the period 1996-1999. 
4 9-5 2     6 5 -80        81 -8 5        8 6 -9 0         9 1 -95       96 -9 9
n = 1 1       n = 1 2         n = 1 0        n = 1 0         n = 3 8          n = 4 7
In t roduct ion o f  vacc inat ion
6 7                7 0               9 0               1 9             3 0
3 7             4 0
39              26
5 5            3 3                3 0               1 0                3 4
4 5                                                               3
M L S T -1
vacc ine  type
M L S T -2
vacc ine  type
M L S T -3
M L S T -4
M L S T -5
p r n 1
p r n 2
p r n 3
P e r iod
 
Fig. 2. MLST frequencies in The Netherlands in the period 1949-1999. Frequencies of 
MLST's within the investigated periods are indicated by numbers and bars. The distribution 
of prn alleles within a particular MLST is indicated by distinct segments. 
3   MLST 
 51
 
Fig. 3. MLST frequencies and pertussis notifications in The Netherlands in the period 
1991-1999. Pertussis notifications are from the period May-April. See legend to Fig. 2 for 
further details. 
 
In 1996 a severe pertussis epidemic occurred in The Netherlands, and the 
incidence has remained high since (33)(Fig. 3). To determine if the upsurge 
could be linked to particular MLST’s, the period 1991-1999 was studied in more 
detail. Isolates were stratified in 12 month’s periods: from May to April of the 
following year. These periods encompass the annual epidemic peak that spans 
the calendar year. Only a few isolates from the years 1991, 1992 and 1993 were 
available, and therefore they were pooled (Fig. 3). MLST-4 was observed to 
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dominate in the years 1994 and 1996 comprising 57% and 50% of the isolates, 
respectively. In the years 1991-1993, 1998 and 1999, the majority of isolates 
were represented by MLST-5. In the last 3 years analyzed, MLST-5 expanded in 
frequency from 10% to 64% and 80%. 
 
Global distribution of MLST’s 
For a comparison of the global distribution of MLST’s isolates from Australia, 
Finland, Italy, Japan, The Netherlands and The United States, were compared 
(Table 2). Isolates were stratified in 2 periods, the prevaccination period and the 
period 1990-1999. Strains from the prevaccination period were only available 
from The Netherlands and The United States. As mentioned previously, MLST-1 
and MLST-2 predominated in The Netherlands in the prevaccination period 
(frequencies 45% and 55%, respectively). These MLST’s were also observed in 
high frequencies in the prevaccination era in The United States, when they 
comprised 25% and 50% of the isolates. In The United States, an additional 
MLST was found (MLST-9) in this period, associated with 25% of the isolates. 
Although predominant in the prevaccination era, all 3 MLST’s were found in low 
(0%-10%) frequency in the period 1990-1999 in all countries, except Japan 
where MLST-2 comprised 69% of the isolates. In the period 1990-1999, 8 
MLST’s were found in the 6 countries compared. The frequencies of the MLST’s 
differed between countries. MLST-4 dominated in Australia and Italy with 
frequencies of 56% and 60%, respectively. MLST-3 dominated in Finland 
(frequency 89%), while MLST-5 dominated in The United States representing 
60% of the isolates. MLST-4 and MLST-5 were found in approximately equal 
frequencies (32% and 38%) in The Netherlands in this period. 
 
Linkage between MLST’s and prn alleles 
For MLST’s, which were observed ³ 3 times in a country, linkage with prn alleles 
was determined in the period 1990-1999 (Table 3). A non-random association 
between MLST’s and prn alleles was observed (P<0.0001). MLST-4 was 
associated with a single prn allele (prn3). MLST-2 was linked with prn1 (92%) 
3   MLST 
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and prn2 (8%). MLST-3 was linked with prn1-5, while linkage with prn2 was 
most frequent (67%). Finally, MLST-5 was associated with prn1-3, with linkage 
with prn2 (92%) being most frequent. 
 
Table 3. Linkage between MLST’s and prn alleles in the period 1990-1999a. 
prn alleles MLST 
 
 
Country 
 
 prn1 prn2 prn3 prn4 prn5 
Number 
of 
isolates 
MLST-2 Netherlands 100% (3)     (3) 
  Japan 89% (8) 11% (1)    (9) 
  total 92% (11) 8% (1)    (12) 
MLST-3 Netherlands 35% (7) 61% (13) 4% (1)   (21) 
  Finland 4% (1) 84% (20) 8% (2) 4% (1)  (24) 
  Italy   25% (1)  75% (3) (4) 
  total 16% (8) 67% (33) 8% (4) 2% (1) 6% (3) (49) 
MLST-4 Netherlands   100% (27)   (27) 
  Finland   100% (3)   (3) 
  Italy   100% (6)   (6) 
  Australia   100% (5)   (5) 
  
total   
100% 
(41)   (41) 
MLST-5 Netherlands 3% (1) 93% (30) 5% (2)   (33) 
  
United 
States  
100% (6) 
   (6) 
  total 3% (1) 92% (36) 5% (2)   (39) 
a Linkage was determined form MLST’s which were identified ³ 3 times in a country. The 
association between MLST and prn alleles was non-random (c2-test, P < 0.0001). Numbers 
of isolates analyzed are between parentheses. 
 
DISCUSSION 
 
In view of the restricted polymorphism found in B. pertussis house keeping 
genes (150)(data not shown), we attempted to increase the likelihood of 
identifying allelic variation by analysis of genes coding for surface proteins, 
which are subject to more intensive selective pressures. Our data provide the 
first global analysis of polymorphism in all 5 components used for ACVs. We 
confirmed previous observations that PtxS1 and Prn were polymorphic 
(19;82;88;92). Interestingly, although PtxS1 was polymorphic, the other 4 
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protein subunits of pertussis toxin were monomorphic. Only one, silent, 
mutation was detected in the gene for PtxS3. This suggests that the S1 subunit 
is subject to more intense (immunological) pressure. This suggests that the S1 
subunit is more immunogenic compared to the other Ptx subunits, and/or that 
antibodies to PtxS1 affect strain fitness more severely. As to the remaining 
components of ACVs, a single non-silent mutation was observed in the genes for 
FHA and Fim2, while the gene for Fim3 was monomorphic. All Dutch isolates 
from 1965 or later harbored the fhaB1 and fim2-1, alleles. In conclusion, of the 
5 proteins included in pertussis ACVs, evidence for a mismatch between vaccine 
strains and clinical isolates was only found for Ptx and Prn (19;56;82;88;92). An 
important question is whether the observed mismatches affect the efficacy of 
pertussis vaccines. Using a mouse model, we have found that variation in Prn 
affects the efficacy of a WCV (69). One may argue that, since ACVs induce 
higher titers against Ptx and Prn compared to WCV, they may be less affected by 
the mismatch. On the other hand, protection conferred by ACVs is based on only 
a few proteins, while WCV induces a much broader immunity based on antigens 
(such as LPS), which are highly conserved. Both types of vaccines are now used, 
and a comparison of countries using either a WCV or an ACV, may resolve this 
issue in the future. 
We also studied polymorphism in a number of surface-associated proteins, which 
are not found in ACVs: BipA, BrkA, TcfA, OmpP, OmpQ and Vag8. No 
polymorphism was detected in brkA and ompP, and with the exception of tcfA, 
polymorphism in the remaining genes was limited. Two alleles were observed for 
bipA, ompQ and vag8, only one of which was found in the period 1965-1999 in 
The Netherlands. The lack of polymorphism in the selected surface proteins was 
unexpected, as some of them have been implicated in immunity. E.g. micelles 
containing TcfA and Vag8 were protective in the intracerebral mouse test if low, 
non-protective amounts of Ptx, were added (60). OmpP is the major outer 
membrane protein of B. pertussis (6). High titers of bactericidal antibodies 
directed against OmpP were induced after vaccination with micelles in mice 
suggesting it may represent an effective vaccine component (107). The 
monomorphic nature of B. pertussis OmpP is unlikely to be due to structural 
constraints, as 0.4-1% divergence was observed with its B. bronchiseptica and 
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B. parapertussis homologues. Thus this work identifies a number of conserved 
proteins, which may be effective vaccine components. 
Five tcfA alleles were identified. The tcfA1 allele contains a 60 bp segment 
flanked by 2 direct repeats. The 60 bp segment and 1 repeat was not found in 
the tcfA2-5 alleles, and it seems likely that it was deleted by recombination 
between the repeats. Since deletion of a sequence between 2 direct repeats is a 
more likely event than duplication of a non-repeated sequence, tcfA1 is probably 
the progenitor of the tcfA2-5 alleles. Interestingly, tcfA1 is found in the 18323 
strain, an atypical B. pertussis strain (13), sometimes erroneously classified 
more closely to B. bronchiseptica than to B. pertussis. We speculate that the 
18323 strain may be closely related to the original B. bronchiseptica strain, from 
which B. pertussis evolved (96;150). Homologues of tcfA were also found in the 
B. bronchiseptica and B. parapertussis genomes (www.sanger.ac.uk). The tcfA5 
allele contained a frame shift mutation in a homo-polymeric G-track, suggesting 
that it is subject to phase variation. Homo-polymeric G- or C-tracks have been 
shown to be involved in fimbrial phase variation at the transcriptional level in B. 
pertussis (158). 
We sequenced 27,862 bases derived from 15 gene segments. In total we found 
23 point mutations and 4 insertions/deletions in 28 polymorphic loci indicating a 
very low degree of polymorphism in B. pertussis. For Mycobacterium 
tuberculosis, also a very homogeneous species, the lack of diversity has been 
suggested to be due to an evolutionary recent origin and worldwide spread of a 
clone in an episode of periodic selection (128). It is presumed that the agent of 
tuberculosis arose from the very closely related cattle pathogen Mycobacterium 
bovis by host specialization occurring since the domestication of this animal 
some 8,000-10,000 yrs ago (67). In a similar vain, the lack of allelic 
polymorphism in B. pertussis is consistent with this species evolving from a 
subset of B. bronchiseptica, which has adapted to the human host relatively 
recently (96;150). 
The virtual absence of silent mutations in B. pertussis implicates that most 
amino acid variations observed increase strain fitness. The lack of polymorphism 
in B. pertussis surface-associated proteins in recent clinical isolates underlines 
the significance of the variation found in Prn, PtxS1 and TcfA. The polymorphic 
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loci in these proteins may interact directly with the immune system or other host 
targets, such as receptors used for attachment. In the period 1990-1999, most 
variation was observed in Prn and TcfA. Many studies have shown the important 
role of Prn in protective immunity (21;23;131). We have found that the Dutch 
whole cell vaccine is less effective against strains, which produce non-vaccine 
Prn types (69). Intranasal vaccination with an attenuated Vibrio cholera strain, 
expressing TcfA, resulted in a significant reduction in tracheal colonization, while 
colonization in the lungs was not affected, suggesting that antibodies to TcfA 
may be effective in conferring protection (22). 
MLST has proven to be useful to study the epidemiology of bacterial pathogens 
(39;44;65), and we categorized B. pertussis isolates in MLST’s, based on 
polymorphism in ptxS1, ptxS3 and tcfA. Prn was not included in the MLST 
scheme, as variation is based on recombination within the repeated region or 
slipped strand mispairing, phenomena, which occur at relatively high frequency. 
Interestingly, the prn alleles were not distributed randomly over the MLST’s 
(P<0.0001). Focusing on the 3 MLST’s, which comprise a sufficient number of 
analyzed strains (i.e. 35-48) the following can be observed. MLST-3 and MLST-5 
were associated with 5 and 3 prn alleles, respectively (Table 3). However, prn2 
predominated within these MLST’s, (frequency 67% and 92%, respectively). In 
contrast, MLST-4 was found associated with the prn3 allele only. Gupta et al. 
have shown that pathogen populations may segregate into discrete strains with 
non-overlapping antigenic structures, if these structures are immunodominant 
(57). Thus the non-random association of prn alleles with MLST’s, may reflect 
strong immune selection focused on Prn and other (as yet unknown) B. pertussis 
antigens.  
In accordance with our previous studies using IS1002 based RFLP, MLST 
analysis revealed large changes in the bacterial population subsequent to the 
introduction of WCV in The Netherlands and The United States (19;151;153). 
MLST-1 and MLST-2, corresponding to the 2 vaccine strains, were predominant 
in the prevaccination period, but only detected in very low frequency in the B. 
pertussis population in subsequent periods. A plausible explanation for this 
phenomenon is that vaccination has shifted the competitive balance between 
strains, and selected for variants less affected by vaccine-induced immunity. In 
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1996 there was a severe epidemic of pertussis in The Netherlands, and the 
incidence has remained high since (33). MLST did not reveal obvious differences 
between the bacterial populations from 1991-1995 and 1996-1999, respectively. 
This may be due to lack of appropriate markers in our MLST system. 
Alternatively, the relationship between epidemics and bacterial strains may be 
complex, and involve factors unrelated to the bacterial population, such as 
changes in surveillance, host immunity and changes in vaccine quality. However, 
a more detailed analysis of the period 1991-1999 did reveal interesting trends. 
The twofold increase in notifications in 1994 compared to 1991-1993 was 
associated with an increase in frequency of MLST-4 from 25% to 57%. The 10-
fold increase in notifications in 1996 compared to 1995 was associated with an 
increase in frequency of MSLT-4 from 33% to 50%. Also in 1998 and 1999 there 
was a substantial increase in notifications compared to 1997 (1,9 and 3,2 fold, 
respectively), associated with an expansion of MLST-5 from 10% in 1997 to 
64% and 80% in 1998 and 1999, respectively. This suggests that epidemic 
years are associated with clonal expansion of particular strains. The expansion of 
MLST-5 is particularly remarkable. MLST-5 is identical to MLST-3 except for a 
silent mutation in ptxS3, and while MLST-5 increased in frequency from 10% in 
1997 to 80% in 1999, the frequency of MLST-3 reduced from 50% to 20% in the 
same period. Since the mutation in ptxS3 is very likely neutral, the distinctive 
behavior of these 2 MLST’s must be due to an as yet unidentified polymorphic 
locus, which has a strong affect on strain fitness. We are currently trying to 
identify this locus. The identification of strains, which expand in epidemic years, 
illustrates the value of MLST analyses.  
We extended our MLST analysis to include a number of widely separated 
geographic regions, including Australia, Finland, Italy, Japan and The United 
States. MLST-4 and MLST-5 were found to dominate in Australia, Italy and The 
United States (Table 2). Significantly, these MLST’s predominated in years with 
the highest pertussis notifications in The Netherlands. However, in contrast to 
The Netherlands, where both MLST’s were present in approximately equal 
frequencies in the period 1990-1999 (32% and 38%, respectively), only one 
type predominated in Australia, Italy and The United States. In Finland a third 
MLST (MLST-3) was found to predominate, comprising 89% of the isolates. In 
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Japan, MLST-2 comprised 69% of the isolates. Thus, although each region 
showed distinctive MLST frequencies, in 4 of the 6 regions MLST-4 and MLST-5 
were predominant. Of the 4 regions, in which MLST-4 and MLST-5 
predominated, 3 (Australia, The Netherlands and The Unites States) have 
reported an increased pertussis incidence (3;8;33;58). MLST-4 and MLST-5 may 
represent, newly emerged, successful clones. Further, analysis of strains 
belonging to MLST-4 and MLST-5 may reveal why B. pertussis has remained 
such a successful pathogen, despite intensive vaccination. 
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ABSTRACT 
 
espite the introduction of mass vaccination in 1953 in The Netherlands, 
pertussis is currently an endemic disease with regular epidemic outbreaks. 
Here we studied changes in the Bordetella pertussis population in the first 20 
years after the introduction of vaccination by indexing IS1002 fingerprint types, 
fimbrial serotypes and 15 genes coding for surface proteins. We compared three 
periods, the prevaccination period (1949-1952) and two subsequent periods 
1953-1958 and 1965-1972. Except for fimbrial serotypes, there were no 
changes between the first two periods. Mortality decreased 5-fold and 543-fold 
in the periods 1953-1958 and 1965-1972, respectively, compared to the 
prevaccination period. The large decrease in mortality coincided with significant 
changes in the B. pertussis population with respect to the frequencies of fimbrial 
serotypes, fingerprint types and ptxS1 alleles. A new fingerprint type (ft 29), 
associated with the novel ptxS1 allele, ptxS1A, was observed in 50% of the 
isolates in the period 1965-1972. Of the 15 investigated genes, only ptxS1 
showed a mismatch between the vaccine strains and clinical isolates, suggesting 
that it played an important role in driving the observed changes. Our results 
suggest that, within 10-20 years after the introduction of mass vaccination, an 
adaptive response occurred consisting of clonal expansion of strains, which 
expressed a pertussis toxin variant distinct from the vaccine variants. This 
adaptation had very little, if any, effect on mortality, however. 
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INTRODUCTION 
 
n The Netherlands, pertussis is an endemic disease with regular epidemic 
outbreaks despite the fact that most children have been vaccinated against 
pertussis since 1953 (33;34). A remarkable increase in the pertussis incidence 
was observed since 1996 (33). In other countries a re-emergence of pertussis 
has also been observed (3;8;36;58). Further, although morbidity and mortality 
is highest in newly born and children, pertussis is now recognized as an 
important infectious disease of adults (17;58;122;132).  
The B. pertussis population changed significantly after the introduction of 
vaccination in a number of countries (19;82;88;92). Antigenic divergence 
between clinical isolates and vaccine strains was observed, suggesting that 
adaptation of the B. pertussis population to vaccine-induced immunity may be 
an important factor in the resilience of B. pertussis against vaccination. DNA 
fingerprinting revealed two decreases in the genotypic diversity of the Dutch B. 
pertussis population, in the periods 1950-1972 and 1982-1996, which were 
associated with the emergence of novel pertussis toxin and pertactin types, 
respectively (153). These types were antigenically distinct from the type(s) 
present in the pertussis vaccine, suggesting that the novel strains were escape 
variants. 
Changes in the B. pertussis population in the 1950s, the period when pertussis 
vaccines were introduced, are particularly interesting as they may illustrate how 
pathogens adapt to mass vaccination within a short time span. In the period 
1949-1972, changes in frequencies of alleles for the S1 subunit of pertussis 
toxin were observed (92). Thus expansion of escape variants may have 
contributed to the observed decrease in genotypic diversity. However, only a 
limited number of strains and genes coding for immunologically relevant proteins 
were analyzed. Here we investigated changes in the B. pertussis population 
structure in this period in greater detail. Further, we looked for evidence that 
strain adaptation affected mortality.  
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MATERIAL AND METHODS 
 
Strains 
B. pertussis strains were collected in The Netherlands from 1949 to 1972. Most 
strains were sent to the RIVM by regional laboratories for serotyping or 
confirmation of identification. Strains were stored lyophilized or as a suspension 
at –70 0C. A potential problem was the selection of epidemiologically related 
strains. Therefore, whenever possible, we selected those strains which, based on 
year or place of isolation were epidemiologically unrelated. Strains were restored 
by growth on Bordet Gengou agar (DIFCO, 0048-15-7) supplemented with 1% 
glycerol and 15% sheep blood at 35 0C for 3 days.  
 
DNA Sequencing 
PCR conditions for the amplification of ptxS1 and prn were described previously 
(92). The amplification of the tcfA and fim2 gene and the 500 bp fragment of 
fhaB, which contained the polymorphic locus was performed in 20 µl, containing 
1 µl of DNA and 19 µl buffer comprising 50% HotstarTaq Master mix (Qiagen, 
Germany), 1 µM of each primer and 5% dimethyl sulfoxide. The tcfA gene from 
5 strains was sequenced completely. Two polymorphic regions were identified 
between bases 1 and 945, which were amplified with the primers tcfAF 
(TTCTTGCGCGTCGTGTCTTC) and tcfAR3 (GCGGTTGCGGACCTTCAT). A region 
comprised of bases 395-945 was sequenced for all strains with primers tcfAR3 
and tcfAF2 (TCGTCTGGCGGACATAACCC). As polymorphism in the region 
comprised of bases 1-395 appeared to be linked to polymorphism in region 395-
945 (i.e. was non-informative), it was sequenced for 1 out of 5 Dutch strains 
with primer tcfAF. Primers used for amplification and sequencing of fim2 were 
fim2for (GCGCCGGGCCCTGCATGCAC) and fim2rev (GGGGGGTTGGCGATT-
TCCAGTTTCTC). For fhaB primers fha9F (ATCTCCGGCGAGGGG) and fha4450R 
(CGGTGTAATCGCCCTGTATC) were used for amplification and primers fha39R 
(GATTGGCGTGCAGCGAGTTC) and fha41R (GGCTAGCGCTGGCTCTGTCC) were 
used for sequencing. PCR amplification was performed by preheating the 
samples 15 min at 95oC. Subsequent amplification of tcfA was performed by 
heating the samples 15 sec at 95oC, initial annealing at 72oC for 15 sec and 
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elongation for 1 min at 72oC. The annealing temperature was decreased every 
two cycles with 2oC until 62oC. Amplification of fim2 was performed by heating 
the samples 15 sec at 95oC, initial annealing at  67oC for 15 sec and elongation 
for 1 min at 72oC. The annealing temperature was decreased every cycle with 
1oC until 62oC. Amplification of fhaB was performed by heating the samples 15 
sec at 95oC, initial annealing at 65oC for 15 sec and elongation for 4 min at 
72oC. The annealing temperature was decreased every two cycles with 2oC until 
55oC. The cycle with the final annealing temperature was repeated 25 times. 
Final elongation was performed for 10 min at 72oC. PCR fragments were purified 
with Qiaquick (Qiagen, Germany). Sequence reactions were performed with an 
ABI Prism Big Dye terminator reaction kit and the reactions were analyzed with 
a model 377 or 3700 ABI DNA Sequencer (Perkin-Elmer Applied Biosystems). 
 
Serotyping 
On a grease-free slide, bacterial colonies were emulsified in a drop of serum that 
contained Fim2 or Fim3 polyclonal antibodies, after which agglutination was 
determined macroscopically. To examine auto-agglutination the drop of serum 
was replaced by physiological saline. 
 
IS1002 DNA fingerprinting 
IS1002-based DNA fingerprinting was performed as described previously by 
digesting chromosomal DNA with Sma1 (153). The samples were analyzed on 
agarose gels (Pulse Field Certified, Biorad, USA), which were transferred to 
Hybond+ membrane (Amersham Pharmacia Biotech, Sweden) using standard 
DNA blotting techniques. A 293 bp IS1002 probe was used for hybridization. 
Labeling of the probe with peroxidase and detection of hybridizing bands was 
performed according to the instructions of Enhanced Chemiluminescence Gene 
Detection System (Amersham Pharmacia Biotech, Sweden). The exposed films 
were scanned at 190 DPI (HP Scanjet IIcx/T, Hewlet Packard, USA). The films 
were analyzed using the Bionumerics software (Applied Maths, Belgium). 
Pairwise similarities of IS1002 fingerprint patterns were calculated using the 
Dice coefficient of similarity. Clustering of the isolates was carried out with 
UPGMA.  
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Genotypic diversity (GD) was calculated with the following equation: GD={n/n-
1}(1-Sxi
2), whereby n is the number of strains and xi  is the frequency of ith 
fingerprint type (100). 
 
Statistical analysis 
The statistical significance of the ptxS1 frequencies and differences in fimbrial 
serotypes and fingerprint types between periods were calculated by applying c2 
test. To comply with the conditions for the c2 test the analysis was performed on 
the summed fingerprint types of the clades. The significance of the genotypic 
diversity was estimated as follows. By computer simulation we randomly 
generated 1000 cross-tabulations similar to Fig. 3, under the null hypothesis of 
no differences in frequency of fingerprint types between periods or ptxS1 allele 
groups. Under that hypothesis, fingerprint types essentially occur at random in 
the different periods or in ptxS1 groups. We then counted the number of times 
the squared differences in genotypic diversity in the simulated tables exceeded 
the observed squared difference and used these counts (divided by 1000) as an 
estimate of the P value of the difference in genotypic diversity. 
 
RESULTS  
 
Polymorphism in genes coding for surface proteins in the period 1949-
1972 
Previously we investigated whether polymorphism occurred in 15 genes coding 
for B. pertussis surface proteins. In the Dutch B. pertussis population, 
polymorphism, resulting in amino acid changes, was detected only in fim2, fhaB, 
prn, ptxS1 and tcfA. To determine whether changes in allele frequencies 
occurred in the period 1949-1972, these genes, or their polymorphic segments, 
were sequenced for a selection of strains. Only 1 tcfA allele was observed in the 
investigated period (n=27). Two fim2 (fim2-1 and fim2-2), 2 fhaB (fhaB1 and 
fhaB2) 3 prn (prn1, prn7 and prn10) and 4 ptxS1 (ptxS1A, ptxS1B, ptxS1D and 
ptxS1E) alleles were observed (Fig. 1). The prn7, fim2-2 and fhaB2 alleles were 
found to be associated with ptxS1D, while prn1, fim2-1 and fhaB1 were linked to 
2 other ptxS1 alleles (ptxS1A and ptxS1B). The ptxS1E allele was linked to 
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prn10, fim2-1 and fhaB2 (n=1) and was not detected previously in the Dutch B. 
pertussis population. The prn10 allele was not described previously, and 
contains an additional GGAVP repeat in region 1 compared to prn6. Thus, the 
following allelic combinations were observed: [fim2-2, fhaB2, prn7, 
ptxS1D](n=9), [fim2-1, fhaB1, prn1, ptxS1B](n=12), [fim2-1, fhaB1, prn10, 
ptxS1E](n=1) and [fim2-1, fhaB1, prn1, ptxS1A](n=8). Since each allelic 
combination could be unambiguously identified by sequencing ptxS1 only, we 
focused on ptxS1. The ptxS1 gene was sequenced for 66 strains. 
 
pertussis toxin gene cluster (3121 bp)                                 
           S1               S2         S4       S5       S3 
 
 
  
    
 
   199              583     679 
ptxS1D  CTC GAA CAT CTG -//- TAT TCC AAC -//- CGC ATG GCG CCG GTG GTG GGC  
         L   E   H   L        Y   S   N        R   M   A   P   V   V   G 
ptxS1E  ... ... ... ... -//- ... C.. ... -//- ... ... ... ... ... A.. ... 
                                  P                                M 
ptxS1B  ... ..C ... ... -//- ... ... ... -//- ... ... ... ... ... A.A ... 
             D                                                     I 
ptxS1A  ... ..C ... ... -//- ... ... ... -//- ... ..A ... ... ... A.A ...  
             D                                     I               I     
Fig. 1. The ptxS1 alleles found in the Netherlands in the period 1949-1972. Dots indicate 
identity. The numbers indicate the position of the underlined nucleotide relative to the 
start of the gene. 
 
Strains were stratified in 3 periods: 1949-1952, 1953-1958 and 1965-1972 and 
the frequency of ptxS1 alleles in each period was determined (Table 1). The 
period 1959–1964 could not be investigated, due to lack of isolates. Large-scale 
vaccination in The Netherlands was started in 1953, and hence the period 1949-
1952 represented the prevaccination period. In this period two ptxS1 alleles, 
ptxS1B and ptxS1D were found in 58% and 42% of the isolates, respectively. In 
the subsequent period 1953-1958, ptxS1B and ptxS1D comprised 50% and 43% 
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of the isolates, respectively. The ptxS1E allele was found only once (7%) in the 
period 1953-1958. The frequencies of ptxS1 alleles were not significantly 
different between the periods 1949-1952 and 1953-1958. (P=0.4). In the period 
1965-1972 a shift was observed relative the previous period (1953-1958 vs. 
1965-1972, P<0.0001). The frequency of ptxS1B decreased from 50% to 29%, 
while ptxS1D disappeared completely. Further, a new variant, ptxS1A, was 
observed in the period 1965-1972, which comprised 71% of the isolates (Table 
1). 
 
Table 1. Frequencies of ptxS1 alleles and fimbrial serotypes in The Netherlands 
in the period 1949-1972a. 
Total period allele/ 
serotype  1949-1952 1953-1958 1965-1972 
ptxS1A 30% (20) 0% (0) 0% (0) 71% (20) 
ptxS1B 44% (29) 58% (14) 50% (7) 29% (8) 
ptxS1D 24% (16) 42% (10) 43% (6) 0% (0) 
ptxS1E 2% (1) 0% (0) 7% (1) 0% (0) 
Fim2 22% (13) 29% (6) 38% (5) 8% (2) 
Fim2,3 27% (16) 43% (9) 54% (7) 0% (0) 
Fim3 52% (31) 29% (6) 8% (1) 92% (24) 
a Number of strains analyzed are shown between parentheses. The distribution of ptxS1 
alleles and fimbrial serotypes was analyzed with c2 test. P values for the frequencies of the 
PtxS1 variants: 1949-1952 vs. 1953-1958, P=0.400; 1953-1958 vs. 1965-1972, 
P<0.0001. P values for the frequencies of the fimbrial serotypes: 1949-1952 vs. 1953-
1958, P=0.426; 1953-1958 vs. 1965-1972, P<0.0001. 
 
Fimbrial serotypes 
Fimbrial serotypes (Fim2, Fim2,3 or Fim3) were determined for strains, for 
which the ptxS1 allele was identified (Table 1). In the period 1949-1952, Fim2, 
Fim2,3 and Fim3 comprised 29%, 43% and 29% of the isolates respectively. In 
the subsequent period (1953-1958), a decrease in Fim3 strains was observed 
(to 8%), while the frequencies of Fim2 and Fim2,3 increased to 38% and 54%, 
respectively. The frequencies of fimbrial serotypes were, however, not 
significantly different between the periods 1949-1952 and 1953-1958. 
(P=0.426). The last period (1965-1972) was quite distinct with respect to the 
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frequencies of fimbrial serotypes (P<0.0001, 1953-1958 vs. 1965-1972). Fim3 
predominated in 92% of the isolates, while Fim2,3 was not detected.  
 
IS1002-based DNA fingerprinting  
Strains, for which the ptxS1 allele was identified, were also analyzed by IS1002-
based DNA fingerprinting. Twenty-one fingerprint types were observed, which 
were grouped into 6 (A-F) clades of related patterns with UPMGA (Fig. 2). To 
observe temporal trends, strains were stratified in 3 periods: 1949-1952, 1953-
1958, 1965-1972 (Fig. 3). The first 2 periods did not significantly differ in 
fingerprint frequencies (P=0.507). In these 2 periods most isolates were found 
 
Fig. 2. Dendrogram of fingerprint types found in The Netherlands in the period 1949-
1972. Clustering was performed using UPGMA, and 6 clades (A-F) are indicated. Upper and 
lower bars indicate similarity coefficient and size of fingerprint type fragments in kilobases, 
respectively. 
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Fig. 3.  Frequency of fingerprint types found in the Dutch B. pertussis population in the 
period 1949-1972. The period 1949-1952 represents the prevaccination period. Six clades 
(A-F) are indicated. Bar indicates similarity coefficient. Number of isolates is in 
parentheses. N is number of strains in each period. P values for differences in fingerprint 
type frequencies are (c2 test): 1949-1952 vs. 1953-1958, P=0.507 and 1953-1958 vs. 
1965-1972, P<0.0001. GD, genotypic diversity per period. P values for differences in GD 
are: 1949-1952 vs. 1953-1958, p=0.531; 1953-1958 vs. 1965-1972, p=0.004. Mortality 
rates are given per 100,000. 
 
in clade B (37% and 35%, respectively) and clade E (33% and 42%, 
respectively). The genotypic diversity of 0.87 and 0.90 in these two periods did 
not differ significantly (P=0.531). Although the first 2 periods were very similar, 
there was a significant difference in fingerprint types and frequencies between 
the period 1953-1958 and the period 1965-1972 (P<0.0001). In the period 
1965-1972, most (65%) fingerprint types were found in clade A, while in the 2 
previous periods 9% and 0% of the fingerprint types were found in this clade. 
Further, in this period 50% of the strains was associated with one fingerprint 
10080604020 ptxS1 1949-1952 1953-1958 1965-1972
ft 29 Clade A ptxS1A 50% (14)
ft 38 ptxS1A 7% (2)
ft 35 ptxS1A 4% (1)
ft 33 ptxS1A 4% (1)
ft 79 ptxS1D 8% (2)
ft 14 Clade B ptxS1A 7% (2)
ft 12 ptxS1B 4% (1) 11% (3)
ft 78 ptxS1B 4% (1)
ft 80 ptxS1B 7% (1)
ft 15 ptxS1B 29% (7) 7% (1)
ft 85 ptxS1B 7% (1)
ft 84 ptxS1B 14% (2)
ft 19 Clade C ptxS1B 13% (3) 14% (2)
ft 21 ptxS1B 4% (1)
ft 22 ptxS1B 4% (1)
ft 24 ptxS1B 4% (1)
ft 27 Clade D ptxS1B 14% (4)
ft 45 ptxS1D 8% (2) 14% (2)
ft 43 Clade E ptxS1D 4% (1)
ft 44 ptxS1D 21% (5) 28% (4)
ft 48 Clade F ptxS1E 7% (1)
N 24 14 28
GD 0.87 0.90 0.73
Mortality 1.63 0.34 0.003
ft
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type, ft 29, a type that was not detected previously. The expansion of ft 29 
strains was reflected in the genotypic diversity, which decreased to 0.73 in the 
period 1965-1972 (P=0.004 for 1953-1958 vs.1965-1972). 
 
Linkage between ptxS1 alleles and fimbrial serotypes 
The association between ptxS1 alleles and fimbrial serotypes was random in the 
ptxS1D and ptxS1B group (respectively, P=0,121 and P=0.501) and non-
random in the ptxS1A group (P=0.002)(Table 2). Most notable were the high 
frequencies of linkage between ptxS1D with Fim2,3 (71%) and ptxS1A with 
Fim3 (89%). 
 
Table 2. Linkage between ptxS1 and fimbrial serotypes a. 
 ptxS1 alleles Serotype 
ptxS1D ptxS1B ptxS1A 
Fim 2 14% (2) 30% (8) 11% (2) 
Fim 2,3 71% (10) 22% (6) 0% (0) 
Fim 3 14% (2) 48% (13) 89% (16) 
a P values for the distribution of fimbrial serotypes are (c2 test): P=0.121 for ptxS1D, 
P=0.501 for ptxS1B and P=0.002 for ptxS1A. 
 
Linkage between ptxS1 alleles and fingerprint types 
There was congruence between clustering based on fingerprint types and ptxS1 
alleles (Fig. 3). In clade A, 4 out of 5 fingerprint types were associated with 
ptxS1A. The major fingerprint type in this clade, ft 29, was uniquely associated 
with ptxS1A. In clade B, 6 out of 7 fingerprint types were associated with 
ptxS1B. Clades C, D, E and F harbored only a single ptxS1 allele, respectively, 
ptxS1B, ptxS1B, ptxS1D and ptxS1E.  
 
DISCUSSION 
 
In 1953 large-scale pertussis vaccination was introduced in The Netherlands. 
Since then the WCV has been changed several times (24-26). Initially, vaccine 
strains were grown on solid media. However, in 1958 production was switched 
to liquid media and a new strain was selected (strain 509 fim2-2, fhaB2, prn7, 
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ptxS1D, Fim2,3), which showed a high potency when grown in liquid media 
(24;25). It is not clear, which strain(s) were used previous to 1958. In the early 
sixties a second strain was added to the vaccine (strain 134 fim2-1, fhaB1, prn1, 
ptxS1B, Fim3). The strains 509 and 134 are still used nowadays.  
Of the 15 investigated genes, 4 were found to be polymorphic (i.e. fim2, fhaB, 
prn and ptxS1). Three allelic combinations were observed in the prevaccination 
period and the period 1953-1958: [fim2-2, fhaB2, prn7, ptxS1D], [fim2-1, 
fhaB1, prn1 ptxS1B] and [fim2-1, fhaB1, prn10, ptxS1E]. The first 2 
combinations were present in the 2 vaccine strains, used since the early sixties, 
while the third combination of alleles was observed in 1 isolate only. In the 
1960s, only one allelic combination from the prevaccination period was 
observed, [prn1, fim2-1, fhaB1, ptxS1B], and a novel, 4th, allelic combination 
was found [prn1, fim2-1, fhaB1, ptxS1A]. Thus, the only mismatch we detected 
in the 1960s between the vaccine strains and circulating strains was with respect 
to the PtxS1 subunit, suggesting that it played an important role in driving the 
observed changes in the B. pertussis population. 
In the first period after the introduction of vaccination (1953-1958), no 
significant changes in the frequencies of fingerprint types and the alleles 
investigated were observed (Table 1, Fig. 3). However, changes in frequencies 
of fimbrial serotypes occurred. The prevaccination B. pertussis population was 
characterized by equal frequencies of Fim2 and Fim3 strains (29%), while 
Fim2,3 strains were found at a higher frequency (43%)(Table 1). Similar 
frequencies were found in other countries in the prevaccination period (18;41). 
In the period 1953-1958 a decrease in Fim3 strains was observed to 8%, 
possibly implicating that the vaccine contained a Fim3 strain in this period.  
In the second period after the introduction of vaccination (1965-1972), 
significant changes in frequencies of ptxS1 alleles, fingerprint types and fimbrial 
serotypes were observed (Table 1). The ptxS1A allele, not previously detected, 
was found in 89% of the strains, while ptxS1B was observed in 29% of the 
strains. The ptxS1D allele was not detected in this period. Further, fimbrial 
serotype 3 increased from 8% to 92%. The most notable change in fingerprint 
types was the emergence of ft 29, associated with 50% of the strains. The 
observed changes in the B. pertussis population in the second period after the 
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introduction of vaccination were much more dramatic compared to the first 
period. Mortality was 543-fold and 5-fold lower in the periods 1965-1972 and 
1953-1958, respectively, compared to the prevaccination period (25). This 
suggested that vaccination was more effective in the second period and 
consequently had a greater effect on the B. pertussis population. Further, the 
decrease in mortality indicates that, although vaccination affected the 
competitive balance between strains resulting in the expansion of escape 
variants, the total circulation of B. pertussis was decreased. 
Strains with ptxS1D disappeared before ptxS1B strains (Table 1). This may have 
been due to the fact that early vaccine strains contained the ptxS1D allele (as 
indeed strain 509 does), while the second strain, 134 (with ptxS1B), was added 
to the vaccine in the 1960s (25). It is also possible that the ptxS1B allele 
confers a higher degree of fitness on strains compared to ptxS1D. Consistent 
with this, ptxS1D was not detected in strains from the prevaccination era in the 
United Kingdom and detected in low frequencies (14%) in the United States 
(19;49). In the same period, ptxS1B was found in frequencies of 50% and 81%, 
respectively, in these countries. Although ptxS1A was not detected in the Dutch 
prevaccination population, we presume that it was present in low frequencies, as 
it was found in the prevaccination period in both the United Kingdom and the 
United States (frequencies 50% and 5%, respectively)(19;49). Strains with 
ptxS1A predominate in many countries with a high vaccination coverage (92). 
Most likely, ptxS1A strains were less affected by immunity induced by the 
vaccine strains, which harbor ptxS1B and ptxS1D. However, as yet we cannot 
exclude the possibility that the emergence of ptxS1A strains was (also) caused 
by other (unknown) loci, which increased strain fitness and which were linked to 
ptxS1A. 
The rise to predominance of Fim3 subsequent to the introduction of vaccines 
with both fimbrial serotypes (1960s) was observed not only in The Netherlands, 
but also in other countries (13;18;41;108). It has been suggested by Preston et 
al. that this phenomenon is due to the fact that Fim3 is less immunogenic than 
Fim2 (108;108;109). Since the rise of Fim3 frequency coincides with the rise in 
ptxS1A frequency, it is also conceivable that the Fim3-ptxS1A combination has a 
higher fitness than other Fim combinations with ptxS1A. It is, however, unlikely 
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that fimbriae played a role in the expansion of particular clones. B. pertussis 
contains both fimbrial genes, which are switched on or off randomly by 
insertions or deletions in a homo-polymeric C-track (158). Thus strains can 
switch between fimbrial serotypes with relative high frequency (115). 
In general, there was congruence between clustering based on fingerprint type 
and ptxS1 type (Fig. 3). Two exceptions were observed, strains with ptxS1D and 
ptxS1A were found in clade A and B, in which ptxS1A and ptxS1B predominated, 
respectively. Especially the presence of ptxS1D in clade A was striking, as this 
allele was normally found in clade E, which showed a deep branching point with 
clade A. This observation could be explained by horizontal transfer of ptxS1D to 
a clade A strain, or chromosomal rearrangements resulting in a change in 
fingerprint type (Fig. 2). The ptxS1D allele is generally found associated with 
fim2-2, fhaB2 and prn7, while ptxS1A was linked to fim2-1, fhaB1 and prn1. As 
the ptxS1D strain found in clade A harbored fim2-2, fhaB2 and prn7, it seems 
likely that the close relationship of this strain with ptxS1A strains is due to 
chromosomal rearrangements. Weber et al. and Cassiday et al. studied the 
relationship between B. pertussis strains with PFGE (19;157). In contrast to our 
observation, they did not find congruence between clustering based on PFGE and 
ptxS1 type. However, they did observe an association between PFGE type and 
prn alleles. As changes in prn alleles occurred more recently compared to ptxS1 
(92), this may suggest that fingerprinting based on IS1002-based and PFGE 
reveal slower and faster evolutionary clocks, respectively.  
The genotypic diversity as determined by DNA fingerprinting decreased 
significantly from 0.90 to 0.73 in the periods 1953-1958 and 1965-1972, 
respectively. This may have been caused by an evolutionary bottleneck and/or 
by clonal expansion of particular strains, possibilities that are both consistent 
with the introduction of a vaccine. In the period 1965-1972, 50% of the strains 
belonged to 1 fingerprint type (ft 29), and all of these strains contained the 
ptxS1A allele, indicating that clonal expansion had occurred. The 100-fold 
decrease in mortality observed after the period 1953-1958 suggested a very 
significant decrease in circulation of B. pertussis, and thus an evolutionary 
bottleneck. Thus the balance of evidence suggests that the introduction of 
vaccination resulted in an evolutionary bottleneck and clonal expansion of 
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strains, harboring ft 29, PtxS1A and Fim3. Strains with PtxS1A may have been 
introduced by import, mutation or may have existed at a low frequency before 
the introduction of vaccination. Although we favor the latter possibility, in all 
cases the competitive balance between the strains was changed, most likely due 
to the introduction of vaccination, resulting in a significantly higher fitness of 
PtxS1A strains compared to PtxS1B and PtxS1D strains. 
Although the differences between the ptxS1 alleles are small, it seems likely that 
they affect strain fitness (Fig. 1). All mutations in ptxS1 are non-silent, 
indicating that these alleles have emerged due to positive selection. This is also 
suggested by the observation that one of the polymorphic sites of the PtxS1 
subunit has been implicated in binding to the T-cell receptor (30;120). Hausman 
et al. did not find a difference in the ability of antibodies raised with ACV to 
neutralize pertussis toxin variants derived from B. pertussis and B. 
bronchiseptica (61). However, the effect of variation in PtxS1 on immunological 
memory and cellular immunity has not been studied. The effect of variation of 
PtxS1 on fitness is probably small and may be difficult to study in vitro or in 
animal models.  
Although in The Netherlands mortality due to pertussis decreased in the 1950s 
and 1960s, an increase was observed in the 1990s (data not shown). We have 
observed potentially adaptive mutations in 3 B. pertussis genes since the 
introduction of vaccination: ptxS1, tcfA and prn. Mutations in prn have been 
shown to affect efficacy of a WCV in the mouse model (69). Together, these 
changes may act synergistically, and reduce efficacy of pertussis whole cell 
vaccines. 
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ABSTRACT  
 
he emergence of novel B. pertussis strains was identified as one of the 
possible causes for the resurgence of pertussis in vaccinated populations. 
Antigenic divergence between clinical isolates and vaccine strains was observed 
for several surface proteins, including pertactin (Prn) and pertussis toxin subunit 
1 (PtxS1). The vaccine types Prn1, PtxS1B and PtxS1D were replaced by the 
novel variants Prn2, Prn3 and PtxS1A. In this study we investigated the role of 
Prn in colonizing ability and the effect of variation in Prn and PtxS1 on strain 
fitness. For this purpose, we developed an in vivo competition mouse model, in 
which mice were co-infected with two isogenic strains. One strain served as 
reference (vaccine type) and the other as test strain (novel variant). We 
determined relative fitness (RF) by comparing the colonizing ability of the test 
strain with the reference strain. We first investigated the effect of a pertactin 
knock-out (Prn-ko) mutation on fitness and demonstrate here for the first time 
that a Prn-ko mutation reduced RF compared to the wild type strain. Next we 
studied the natural variation in Prn and PtxS1. We observed that in the upper 
respiratory tract of mice the RF of strains, carrying Prn2, Prn3 and/or PtxS1A, 
was reduced compared to the reference strain, carrying Prn1 and PtxS1B. In the 
lungs, however, the reverse was observed; the RF of the Prn2 and Prn3 strains 
(in combination with PtxS1A) was increased compared to the reference strain. 
We assume that fitness in the nasopharynx and trachea is most relevant for the 
human situation, since B. pertussis primarily is an infection of the upper 
respiratory tract. Thus our data suggest that strains with Prn2, Prn3 and/or 
PtxS1A (carrying non-vaccine type protein variants that predominate in the 
current B. pertussis population), are less fit compared to Prn1, PtxS1B strains 
(carrying vaccine type protein variants predominant in the prevaccination era). 
Vaccination may have changed the competitive balance between strains; due to 
immune pressure, the fitness of strains with Prn2, Prn3 and PtxS1A increased 
relative to strains with Prn1 and PtxS1B. 
  
T
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INTRODUCTION 
 
hole cell vaccines against pertussis, introduced in many countries in the 
1940s and 1950s, have been very successful in controlling this disease. 
However, in the 1990s pertussis re-emerged in a number of countries with 
vaccinated populations such as Australia, Canada, The Netherlands, and The 
United States (3;8;33;34;36;58;59). Further, although morbidity is highest in 
newly born and children, pertussis is now recognized as an infectious disease in 
adults (17;58;122;132). 
The emergence of novel B. pertussis strains was identified as one of the possible 
causes for the resurgence of pertussis (91). Antigenic divergence between 
clinical isolates and vaccine strains was observed for several surface proteins, 
including pertactin (Prn), tracheal colonization factor (TcfA) and pertussis toxin 
subunit 1 (PtxS1)(19;59;82;88;92;157). Several studies have provided 
evidence that Prn and Ptx play an important role in immunity against pertussis. 
Sero-epidemiological studies have shown a correlation between the titer of anti-
Prn antibodies and clinical protection (23;131). Vaccination with a 
monocomponent pertussis toxoid vaccine-induced significant protection for at 
least 2 years and decreased the spread of B. pertussis in a population 
(135;136). Further, the polymorphic sites of Prn and PtxS1 comprise B- and T-
cell epitopes (21;30;69;120). Finally, King et al. have shown that variation in 
Prn affects vaccine efficacy in a mouse model (69). 
In The Netherlands 3 Prn and 4 PtxS1 types were identified Prn1, Prn2 and Prn3, 
and PtxS1A, PtxS1B, PtxS1D and PtxS1E. The vaccine types Prn1, PtxS1B and 
PtxS1D were replaced by the novel variants Prn2, Prn3 and PtxS1A in the 1990s 
(92). The prn2 and prn3 alleles have not been found in strains collected in the 
prevaccination era in a number of countries, while the ptxS1A allele was not 
observed, or observed in low frequencies, in most countries, with the notable 
exception of the United Kingdom, where ptxS1A was found in 50% of the 
prevaccination strains (19;49;88;92;115). We hypothesized that the fitness of 
Prn2, Prn3 and PtxS1A strains was lower in unimmunized populations compared 
to strains with Prn1, PtxS1B and Ptxs1D. Introduction of vaccination may have 
allowed the emergence of novel Prn and PtxS1 variants, because the fitness of 
W
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the vaccine type strains decreased, while that of non-vaccine type strains 
increased, because they were less affected by vaccine-induced immunity. 
In this study we show for the first time that Prn is important for colonization of 
the mice respiratory tract. Further, we investigated the effect of variation in Prn 
and PtxS1 on the ability of B. pertussis to colonize mice. For this purpose, we 
developed an in vivo competition mouse model, in which it was possible to 
detect small differences in colonization efficiency. Further, since clinical isolates 
may differ at many loci, we constructed isogenic strains, which differed only in 
the Prn or PtxS1 type expressed, and an antibiotic resistance marker.  
 
MATERIAL AND METHODS 
 
Construction of strains 
Strains and plasmids used in this study are shown in Table 1 and Table 2. 
Isogenic derivatives of the Tohama strain B213 were constructed by allelic 
exchange. First, two derivatives were constructed by inserting a kanamycin 
(kan) or gentamycin (gen) resistance gene in fim3, a fimbrial gene, which is not 
expressed in the Tohama strain (89). To this purpose, the kan and gen genes 
were inserted into a copy of fim3 contained in pKAS32 (125). The resulting 
plasmid, pKH7-27 or pKH8-62, was transferred to E. coli SM10 (136), which 
allowed subsequent transfer to B. pertussis by conjugation. The plasmid pKAS32 
is not able to replicate in B. pertussis, and selection for kanamycin or 
gentamycin resulted in the isolation of B. pertussis clones, in which pKH7-27 or 
pKH8-62 was inserted into the B. pertussis chromosome by homologous 
recombination. Plating on media with kanamycin and streptomycin, or 
gentamycin and streptomycin, respectively, resulted in excision of pKH7-27 or 
pKH8-62, while the kan or gen gene, respectively, was retained. The insertion 
was checked by PCR and DNA sequencing and 2 strains, B1584 (fim3::kan) and 
B1585 (fim3::gen), were selected for further modification. The Tohama strain 
carried the prn1 allele (69) and Tohama derivatives containing prn2 or prn3 
alleles were constructed using B1585 (prn1, fim3::gen) as parental strain by 
exchange of the polymorphic region (region 1) as follows: Primers PrnM13Xba1 
(GCTCTAGATGTAAAACGACGGCCAGTGGGCG-GGCAGCGGGG) and PrnM13EcoR1 
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Table 1. Strains used in this study. 
Strain 
number 
Derived 
from 
Antibiotic 
resistance 
Genotype Reference 
B213 B.pertussis 
Tohama 
NalR, StrepR prn1, ptxS1B  
B1584 B213 NalR, StrepR, KanR prn1, ptxS1B, fim3::kan this study 
B1585 B213 NalR, StrepR, GenR prn1, ptxS1B, fim3::gen this study 
B1586 B1585 NalR, StrepR, GenR prn2, ptxS1B, fim3::gen this study 
B1587 B1585 NalR, StrepR, GenR prn3, ptxS1B, fim3::gen this study 
B1684 B1587 NalR, StrepR, GenR prn3, ptxS1A, fim3::gen this study 
B1814 B1586 NalR, StrepR, GenR prn2, ptxS1A, fim3::gen this study 
B1686 B213 NalR, StrepR, KanR prn::kan, ptxS1B this study 
MC4100?pir E. coli   Skorpuski et al. 
JM109 E. coli   Promega, USA 
SM10 E. coli KanR  Simon et al. 
 
Table 2. Plasmids used in this study. 
Plasmid Derived 
from 
Antibiotic resistance Genotype Reference 
pKAS46  StrepS, AmpR, KanR bla,kan, rpsL, oriT Scorupski et al.  
pSS1129  StrepS, AmpR, GenR bla, rpsL, oriT,gen Sitbitz et al. 
pKH7-27 pKAS32 StrepS, AmpR, KanR fim3::kan this study 
pKH8-62 pKAS32 StrepS, AmpR, KanR fim3::gen this study 
pKH8-69 pKAS46 StrepS, AmpR, KanR prn2 this study 
pKL-1.1 pKAS46 StrepS, AmpR, KanR prn3 this study 
pIvL4-1.1 pKAS46 StrepS, AmpR, GenR ptxS1A this study 
pSR2-1 pSS1129 StrepS, AmpR, GenR prn PCR fragment this study 
pSR2-1.1 pSS1129 StrepS, AmpR, GenR, KanR prn::kan this study 
 
(GGAATTCCAGGAAACAGCTATGACCCCAGCTCC-GGCGCCTCG) were used to 
obtain PCR products with region 1 from prn2 and prn3. The PCR fragments (307 
and 292 bases in size, respectively) were cloned into pKAS46, resulting in pKH8-
69 or pKL-1.1. Subsequently, the procedure was similar to the insertion of the 
kan and gen genes, as described above, except that it was not possible to select 
for the insert. Therefore, strains, in which region 1 of prn2 or prn3 was inserted, 
were identified by DNA sequencing. Two strains were selected for further 
experiments, B1586 (prn2, fim3::gen) and B1587 (prn3, fim3::gen). The 
Tohama strain harbors the ptxS1B allele, and the same procedure as described 
for prn was used to construct Tohama-derivatives with ptxS1A. A PCR product of 
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the variable region of ptxS1 was amplified using the primers S1AF-Xba1 
(GCTCTAGAGCTTCC-AACGCTCGCTACGTCA) and S1AR2-Xba1 (GGTCTAGAA-
CGAATACGCGATGCTTTCGTAG)(240 basses in size) and was cloned into pKAS46, 
resulting in the plasmid pIvL4-1.1. The latter plasmid was used for allelic 
exchange. Strains containing ptxS1A were identified by sequencing of the 
complete gene. Two strains were selected, B1684 and B1814, which were 
ptxS1A containing derivatives of B1586 and B1587, respectively. To construct a 
Prn knockout mutant (Prn-ko), a PCR product of prn (469 bases in size) was 
amplified using primers PrnXba1F (GCTCTAGAGCCTG-GCATCCAATGAACATGT) 
and PrnEcoR1R (GGAATTCCTGTTCGCCGGCCACATAG), and cloned into pSS1129 
(129), resulting in pSR2.1. Subsequently, the kan gene was cloned into the RsrII 
site located in the prn PCR fragment (pos 184 relative to atg of prn), resulting in 
pSR2-1.1. The latter plasmid was used to introduce the kan gene into prn1 of 
strain B213. Correct insertion was checked by sequencing and one strain, B1686 
was selected for further studies. Expression of Prn and Ptx in all clones was 
confirmed by immunoblotting. 
 
Mouse infection model 
Strains were stored at –80oC and were recovered by growth on Bordet Gengou 
agar (DIFCO, 0048-15-7), supplemented with 1% glycerol, 15% sheep blood 
and 30 µg/ml streptomycin, at 35oC for 24 hrs. Subsequently, a number of 
colonies were transferred to a fresh plate without streptomycin, and incubated 
at 35oC for 24 hrs, after which bacteria were harvested in Verwey medium 
(156). Optical densities of bacterial suspensions were measured at 600 nm and 
adjusted to approximately 1010 bacteria/ml. Finally, the bacterial suspensions 
were flash-frozen in ethanol/dry ice in small aliquots in Verwey medium with 
15% glycerol and stored at –80oC. The viability of the frozen cell suspensions 
was determined twice prior to infection by plating each strain on 4 plates. For 
infection, cells were thawed at RT and mice were infected with 2*107 CFU of a 
single strain, or with 1*107 CFU of each strain, when a mixture of 2 strains was 
used.  
The mixture comprised a reference strain and a test strain, which were marked 
with either a kanamycin or gentamycin resistance gene. The ratio of the 2 
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strains was verified by plating a sample of the inoculum on BG plates 
supplemented with kanamycin or gentamycin. The ratio of the two strains in the 
inoculum varied between 0.7 and 1.2. After recovery of reference and test 
strains from mice, the number of CFUs were adjusted according to the ratio in 
the inoculum. Plating efficiency for BG plates supplemented with kanamycin or 
gentamycin were identical.  
For infection, BALB/c mice (Harlan, OlHsd) 4-6 weeks old, were lightly 
anaesthetized with ether and 20 µl of the inoculum was placed on top of each 
nostril and allowed to be inhaled. After 3 days mice were sacrificed by 
intraperitoneal injection of NembutalR (Sanofi/Algrin). The nasopharynx was 
sampled by flossing the nostrils with a suture, followed by introducing Verwey 
medium from the internal side of the animal, and collecting the first 5 droplets 
from the nostrils. The trachea and lungs were removed. The trachea was 
vortexed in 500 µl Verwey medium with 5 glass pearls for 30 sec at RT. The 
lungs were homogenized in 900 µl Verwey medium for 10 sec at 20,000 rpm 
with a blender (pro scientific, pro200) at RT. For the determination of CFU 
appropriate dilutions were plated on BG plates supplemented with kanamycin or 
gentamycin, and the number of CFUs was determined after 3 days of incubation 
at 35oC. After co-infection, the relative fitness (RF) of the test strain and the 
reference strain was calculated as follows for each mouse: RF= log CFU test 
strain – log CFU reference strain. To determine RF of strains inoculated in 
separate infections, the average CFU of 8 mice infected with the reference 
strain, or the test strain, was determined, and used to calculate the RF as 
described above. Per strain, or strain pair, 8 mice were infected. All data are 
based on at least 3 independent experiments, except for the data from the 
nasopharynx, which were based on 1 or 2 experiment(s).  
 
Statistical analysis 
Means and SEM were calculated of the 10log CFU. Differences in log CFU between 
strains, co-infected in one mouse, were assessed by the paired Student’s t-test 
and differences between strains infected in separate mice and RF of strain pairs 
were assessed by unpaired Student’s t-test. Significance was accepted at the 
P<0.05 level, and all tests were two-tailed. 
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RESULTS  
 
A mouse model to compare strain fitness 
The aim of this study was to determine the effect of variation in the B. pertussis 
surface proteins Prn and Ptx on strain fitness. Differences in the amino acid 
sequences of Prn and Ptx variants, however, are small (Fig. 1) and we 
anticipated that they would have a minor effect on strain fitness, requiring a 
highly reproducible animal model. For this purpose we developed a competition 
model, in which mice were co-infected with two isogenic strains. One of the 2 
strains served as internal reference, while the other was the test strain. The 
reference strain contained prn1 and ptxS1B, the vaccine variants, while the test 
strain varied in prn and/or ptxS1 allele. The advantage of using an internal 
reference is, that variation in absolute counts due to variation in dosage, the 
efficiency of inhalation of the inoculum and the size (or fraction) of the organ 
excised, is corrected for. Further, infection was performed with frozen cell 
suspensions, which retained their viability for extended periods of time, allowing 
reproducible dosage of the number of viable bacteria. With this approach the 
ratio of the two strains in the inoculum varied between 0.7 and 1.2. 
After co-infection the 2 strains were recultured from the mouse nasopharynx, 
trachea and lungs, and their differential ability to persist was calculated as 
follows: relative fitness (RF) = log CFU test strain – log CFU reference strain. As 
the same reference strain was used within an experiment, the obtained value 
allowed comparison of the fitnesses of different test strains. Further, as the test 
strains were isogenic, differences in fitness of test strains could be attributed to 
distinct alleles. Co-infection required that the 2 strains were marked with distinct 
antibiotic resistance genes (kan and gen), and we first investigated, whether the 
2 genes affected strain fitness differently. 
 
The effect of antibiotic resistance genes on fitness of B. pertussis in the 
mouse model 
To investigate the effect of the antibiotic resistance genes, kan or gen, on strain 
fitness, mice were infected with a mixture of 2 strains B1584 (kan) and B1585 
(gen), which were isogenic, except for the antibiotic resistance gene inserted 
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into a silent fimbrial gene (Table 1). Three days after infection the number of 
CFUs of both strains was determined in the nasopharynx, trachea and lungs 
(Fig. 2A, B and C). 
 
Fig. 1. Pertac-
tin (Prn) and 
pertussis toxin 
S1 (PtxS1) 
variants used 
in this study. 
Differences in 
amino acid se-
quence are 
blocked. In the 
Prn sequence, the RGD sequence involved in attachment to host receptors has been 
underlined and the 5 amino acid repeats are separated by dashes. Gaps in the sequence 
are indicated by x. Prn and PtxS1 comprise 911/916 and 270 amino acids, respectively. 
Numbering of amino acids is relative to the N-terminus. 
 
We found that in the nasopharynx and the lungs the kan strain colonized 
significantly better than the gen strain (P=0.015 and P<0.0001, respectively). 
The small difference in CFUs observed in the lung (i.e. 7%), was highly 
significant, illustrating the sensitivity of the approach. No significant difference 
was found in the trachea (P=0.652)(Fig. 2). The RF of the 2 strains used to co-
infect is shown in Fig. 2D. Any significant deviation from zero indicates that gen 
and kan affect fitness differently. The RF value was negative in the nasopharynx, 
indicating that insertion of gen decreased fitness relative to kan, but was very 
close to zero in the trachea and lungs, indicating little or no differential effect. 
To correct for the differential effect of kan and gen, changes in RF due to 
polymorphism in prn and ptxS1 were compared to a reference pair comprised of 
strains differing only in the resistance genes. 
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Fig. 2. Effect of kan and 
gen genes on strain 
fitness in the mouse. Mice 
were infected with a 
suspension containing an 
equal number of CFUs of 
strain B1584 (kan) and 
strain B1585 (gen). After 
3 days, the number of 
CFUs in nasopharynx (A), 
trachea (B) and lungs (C) 
was determined. In Fig. 
2A-C a representative 
result of 1 experiment is 
shown. Relative Fitness 
(D) was calculated as 
described in the text. In Fig. 2D data from all experiments were pooled. The number of 
experiments (x) and the total number of mice (n) are indicated. Box plots encompass 50% 
of the data points (25th to 75th percentile), the thick line indicates the median, whereas 
whiskers show the range of all data. P values are indicated. 
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The effect of inactivation of the prn gene on fitness of B. pertussis in the 
mouse model 
We next determined the 
effect of a pertactin knock-
out (Prn-ko) mutation on 
strain fitness. Mice were 
co-infected with the strain 
pair B1686 (prn::kan) and 
B1585 (prn1, gen) and RF 
of this pair was compared 
with the reference pair, 
comprising B1584 (prn1, 
kan) and B1585 (prn1, 
gen).  
Fig. 3. Effect of a pertactin 
knock-out mutation on strain 
fitness in the mouse. Mice 
were co-infected with a 
mixture of 2 strains: the 
internal reference strain 
B1585 (prn1, gen) in 
combination with the following 
test strains: A. B1584 (prn1, 
kan), B. B1686 (prn::kan). 
The horizontal line indicates 
the median of the RF value of 
B1584. In C mice were 
infected separately with 
B1585 (prn1, gen) and B1686 
(prn::kan). Relevant charac-
teristics of test strains are 
shown below the graphs. For 
the co-infections the RF was calculated per mouse and for the separate infections per 
experiment. Significant P-values are indicated. See legend to Fig. 2 for further details. 
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The RF of the Prn-ko strain (B1686) was significantly reduced in nasopharynx, 
trachea and lungs compared to the reference (B1584), which harbored the wild 
type prn1 gene (Fig. 3; P<0.0001 for all 3 anatomical sites). The largest 
decrease in RF caused by the Prn-ko mutation compared to the reference pair 
was found in the lungs (lungs vs. nasopharynx and lungs vs. trachea P<0.0001). 
No difference in RF was found between the nasopharynx and the trachea 
(trachea vs. nasopharynx P=0.555). Thus, although Prn was important for 
persistence at all 3 anatomical sites, its role was more important in the lungs. 
Our observation that a Prn-ko mutation affected RF was not consistent with 
results published by Roberts et al, who did not find any effect of a Prn-ko 
mutation on persistence in the mouse trachea and lungs (113). Because Roberts 
et al. used a model, in which mice were infected with single strains, we also 
infected mice separately with B1585 (prn1, gen) and B1686 (prn::kan), 
respectively. We confirmed the results of the co-infection: compared to the prn1 
strain, the Prn-ko strain was less well able to colonize nasopharynx, trachea and 
lungs (Fig. 3). Differences in CFUs of the Prn1 and Prn-ko strain in nasopharynx, 
trachea and lungs were significant (respectively, P=0.036, P<0.0001 and 
P<0.0001). To compensate for the differential effect of the antibiotic resistance 
genes, the separate infections were also performed with 2 kanamycin resistant 
strains: B1584 (prn1, kan) and B1686 (prn::kan). The results were similar to 
the separate infections of B1585 (prn1, gen) and B1686 (prn::kan)(results not 
shown). 
 
The effect of natural variation in pertactin on fitness of B. pertussis in 
the mouse model 
We next investigated whether strains, which carried distinct, naturally occurring, 
Fig. 4. Effect of variation in Prn and PtxS1 on strain fitness in the mouse. Mice were co-
infected with a mixture of 2 strains: the internal reference strain B1584 (prn1, ptxS1B, 
kan) in combination with the following test strains: A. B1585 (prn1, ptxS1B, gen), B. 
B1586 (prn2, ptxS1B, gen), C. B1814 (prn2, ptxS1A, gen), D. B1587 (prn3, ptxS1B, gen) 
and E. B1684 (prn3, ptxS1A, gen). Relevant characteristics of test strains are indicated 
below the graphs. The horizontal line indicates the median of the RF value of B1585. See 
legend to Fig. 2 for further details. 
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prn alleles, showed different fitnesses in the mouse model. Mice were co-
infected with the reference strain B1584 (prn1, kan) in combination with B1586 
(prn2, gen) and B1587 (prn3, gen), respectively. The RFs of these strain pairs 
were determined as described above and compared with the reference pair 
B1585 (prn1, gen) and B1584 (prn1, kan) to compensate for the effect of the 
antibiotic resistance gene on fitness. 
In the nasopharynx the prn2 allele (B1586) did not significantly affect RF, 
whereas the prn3 allele (B1587) reduced RF compared to the prn1 allele 
(B1585)(Fig. 4; P=0.128 and P=0.014, respectively). The RF of the prn3 strain 
(B1587) was reduced compared to the prn2 strain (B1586), although this 
difference was not significant (P=0.120). Thus the results obtained with the 3 
strain pairs suggested that prn1 conferred the highest fitness in the 
nasopharynx, while the prn2 allele did not significantly affect RF and prn3 
conferred the lowest fitness relative to prn1, i.e. prn1 = prn2 > prn3.  
In the trachea, the RF of the prn2 strain (B1586) was not affected compared to 
the prn1 strain (1585) (P=0.809). However, as observed for the nasopharynx, 
the RF of the prn3 strain (B1587) was reduced compared to the prn1 (B1585) 
and prn2 (B1586) strains (P<0.0001, in both cases). Based on these results the 
following RF order can be derived for the trachea: prn1 = prn2 > prn3.  
In the lungs RF of both the prn2 (B1586) and prn3 (B1587) strain increased 
compared to the prn1 strain (B1585)(P<0.0001 in both cases). No significant 
difference was observed between the prn2 and prn3 alleles with respect to their 
effect on RF in the lungs (P=0.930). Thus the fitness order in the lungs was prn2 
= prn3 > prn1. 
 
The effect of natural variation in pertussis toxin on fitness of B. 
pertussis in the mouse model 
The effect of the ptxS1 alleles on RF was studied by constructing strains with 
different combinations of prn and ptxS1 alleles (Table 1). The ptxS1A and 
ptxS1B alleles were tested in a prn2 and prn3 background. Mice were co-
infected with the reference strain B1584 (prn1, ptxS1B, kan) in combination 
with B1814 (prn2, ptxS1A, gen) and B1684 (prn3, ptxS1A, gen), respectively.  
5  Strain fitness in mice 
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In the nasopharynx, exchange of the ptxS1B allele by ptxS1A did not 
significantly affect RF of strains with a prn2 background (Fig. 4; compare B1586 
with B1814, P=0.238). However, the combination of ptxS1A and prn2 (B1814) 
conferred a significantly lower RF compared to the combination ptxS1B and prn1 
(B1585)(P=0.023), while a significant effect of prn2 only (B1586) was not 
observed compared to prn1 (B1585). In a prn3 background no effect of the 
exchange of the ptxS1B allele by ptxS1A was observed (Fig. 4; compare B1587 
with B1684, P=0.372). The combination of ptxS1A with prn3 conferred a 
significantly lower RF compared to ptxS1B and prn1 (Fig. 4; compare B1585 
with B1684, P=0.024). 
In the trachea similar effects were observed for replacement of ptxS1B by 
ptxS1A, i.e. a decrease in RF in a prn2 background and no effect on RF in a prn3 
background, respectively (Fig. 4; compare B1586 with B1814 (P<0.0001) and 
B1587 with B1684 (P=0.128)). The allele combinations ptxS1A-prn2 (B1814) 
and ptxS1A-prn3 (B1684) reduced RF compared to the allele combination 
ptxS1B-prn1 (B1585)(P<0.0001 for both). 
In the lungs replacement of ptxS1B by ptxS1A resulted in a significant decrease 
in RF in both a prn2 and prn3 background (compare B1586 with B1814, 
P<0.0001 and B1587 and B1684, P=0.034). However, strains with ptxS1A in 
combination with prn2 or prn3 (respectively, B1814 and B1684) conferred a 
significantly higher RF in the lungs compared to the strain with ptxS1B and prn1 
(B1585)(P=0.007 and P<0.0001, respectively).  
 
DISCUSSION 
 
The aim of this work was to explain the emergence of novel Prn and Ptx variants 
after the introduction of vaccination, a phenomenon observed in geographically 
separated regions (19;59;82;88;92;157). Our approach was to study the effect 
of different prn and ptxS1 alleles on relative fitness (RF) in a mouse model. 
Relative fitness was used in a restricted sense, as the ability to colonize mice 
relative to a reference strain. Because of the small differences in the amino acid 
sequences of the Prn and PtxS1 variants (Fig. 1), we expected small effects on 
strain fitness, requiring a highly reproducible animal model. This was attained by 
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infecting mice with a suspension that contained two strains in equal numbers of 
CFUs, a reference strain and a test strain. The 2 strains were marked with 
different antibiotic resistance genes, allowing discrimination on selective plates. 
Further, the strains were isogenic, except for the prn or ptxS1 alleles. The 
isogenic strains were (assumed to be) identical, except for the changes 
introduced deliberately. However, unlinked mutations may have been 
introduced, which may affect RF. We are currently investigating this possibility 
by reconstructing the parental genotype by back mutation, which should restore 
the original fitness. The sensitivity of this approach is illustrated by the finding 
that very small differences in CFUs recovered from mice (e.g. 7%), were found 
to be highly significant. Further, in our model we were able to observe 
significant effects of single amino acid substitutions on RF at 3 anatomical sites, 
nasopharynx, trachea and lungs. We assume that fitness in the nasopharynx 
and trachea is most relevant for the human situation, since B. pertussis 
primarily is an infection of the upper respiratory tract. However, in severe cases 
B. pertussis may colonize the lungs (126) and/or secondary complications as 
pneumonia might occur. 
The antibiotic genes affected RF differently in the nasopharynx and lungs of 
mice, but not in the trachea, a phenomenon we cannot as yet explain. We 
compensated for this effect by relating all changes in RF to a strain pair differing 
only in the antibiotic gene inserted. 
To our knowledge we demonstrate here for the first time a role for Prn in fitness 
of B. pertussis in an animal model. We found that the RF of a pertactin knock-
out (Prn-ko) strain was decreased in nasopharynx, trachea and lungs of mice 
(Fig. 2). Roberts et al. did not observe an effect of a Prn-ko mutation in mouse 
trachea and lungs, using a model, in which mice were infected with a single 
strain (113). We also infected mice with the Prn-ko and wild type strain 
separately and observed results similarly to the mixed infections. The 
discrepancy between the work of Roberts et al. and our work might be due to 
differences in the method of infection (aerosol vs. intranasal) or differences in 
strains used to construct a Prn-ko (Wellcome vs. Tohama). 
5  Strain fitness in mice 
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Although the reduction in RF was highly significant at all 3 anatomical sites, the 
largest decrease was observed in the lungs. This suggests that, at least in the 
mouse model, Prn plays an important role in colonizing the lung.  
We observed that small changes in Prn (i.e. substitution of 2, or the insertion of 
5 amino acids, (Fig. 1) affected RF. Interestingly, this effect was dependent on 
the anatomical site. E.g. while Prn1 strains were fitter in the nasopharynx and 
trachea compared to Prn3 strains, the reverse was observed in the lungs. This 
suggests that Prn may have different functions or recognize different receptors 
in the upper and lower respiratory tract. The variable region of Prn is located 
close to the RGD sequence involved in attachment to host receptors (43;74;75), 
and it is likely that variation affects this process. 
The effect of prn alleles on strain fitness in trachea and nasopharynx showed 
interesting parallels with epidemiological data. We observed that the RF 
conferred by prn alleles in the mouse upper respiratory tract was highest for 
prn1 and prn2 and lowest for prn3. Prn1 was found in higher frequencies in non-
vaccinated children compared to those that were vaccinated (92). Further, Prn1 
strains were predominant in the prevaccination era (92). Both observations 
suggest that Prn1 strains are more fit than Prn2 and Prn3 strains in 
unvaccinated populations. After the introduction of vaccines based on Prn1 
strains, Prn2 and Prn3 emerged and largely replaced Prn1. The frequencies of 
Prn1, Prn2 and Prn3 in vaccinated populations might reflect the level of Prn1 
antibodies induced by vaccines. In vaccinated populations, Prn2 generally occurs 
in higher frequencies compared to Prn3 (19;59;82;88;92;157). This suggests 
that Prn2 confers a fitness, intermediate between Prn1 and Prn3. The 
observation that Prn3 confers a lower RF in the mouse upper respiratory tract 
suggest that Prn3 may be found in populations, in which vaccines are used, 
which induce high levels of Prn antibodies. Indeed, after the introduction of 
ACVs, which induce higher levels of Prn antibodies than WCV (37), in Sweden 
the frequency of Prn3 strains rose from 2% to 20% in 5 years (Hans Hallander, 
personal communication). In contrast, in Japan where ACVs are used that induce 
low amounts of Prn antibodies, Prn1 predominates, while Prn2 is found in low 
frequencies and Prn3 has not yet been detected (56;154). Thus vaccination may 
have changed the competitive balance between strains; due to immune 
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pressure, the fitness of Prn2 and Prn3 strains increased relative to Prn1 strains, 
after the introduction of Prn1 containing vaccines. 
In the lungs the fitness of the Prn2 and Prn3 variants increased relative to Prn1. 
The significance of this observation for the biology of B. pertussis is not clear. 
However, as B. pertussis is found in the lungs of patients in severe cases (126), 
it might indicate that Prn2 and Prn3 strains are potentially more virulent than 
Prn1 strains. 
Most vaccine strains harbor the ptxS1B and ptxS1D alleles, which were 
predominant in the prevaccination B. pertussis population (19;88;92). However, 
after the introduction of vaccination ptxS1A emerged and largely replaced the 2 
vaccine types. Nowadays, most strains harbor ptxS1A in combination with prn2 
and prn3. Therefore, we studied the effect of replacement of ptxS1B with 
ptxS1A. This replacement decreased RF in a prn2 background in the 
nasopharynx, trachea and lungs (only significant in trachea and lungs). In a 
prn3 background replacement of ptxS1B with ptxS1A resulted in a decrease in 
RF in the lungs, while no significant effects were observed in nasopharynx and 
trachea. The prn2, ptxS1A and prn3, ptxS1A strains (harboring the allele 
combinations that predominate in the current B. pertussis population), were less 
fit compared to prn1, ptxS1B strain (representative of strains from the 
prevaccination era) in the nasopharynx and trachea. In the lung the reverse was 
observed. As discussed above, vaccination may have shifted the competitive 
balance by decreasing the fitness of strains harboring alleles that are present in 
vaccine strains (i.e. prn1 and ptxS1B). The observation that the effect of 
exchange of ptxS1 alleles was dependent on the prn allele may suggest that Prn 
and Ptx cooperate. 
The frequency of strains is a function of their fitness in immune (vaccinated or 
naturally infected) and non-immune individuals. Introduction of vaccination has 
resulted in a shift in competitive balance between B. pertussis strains. In the 
case of B. pertussis changes in the population structure were observed 10 to 30 
years after the introduction of vaccination. Thus, the consequences of altering 
levels of pathogen competition by vaccination may generally become obvious 
only on time scales longer than those of clinical trials. It is, therefore, important 
to develop mathematical models (63;145) or animal models, as presented here, 
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in which these processes can be studies in a shorter time frame. We are 
currently using this model to compare fitness of Prn and Ptx variants in 
immunized mice to gain insight in shifts in fitness due to vaccination. 
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ABSTRACT 
 
lthough vaccination against pertussis in The Netherlands was very effective 
during 45 years, the disease has shown a remarkable comeback in the 
1990s. Several studies showed that the B. pertussis population changed after 
the introduction of vaccination. Polymorphism in genes coding for surface 
proteins was observed, and temporal trends revealed antigenic divergence 
between vaccine strains and clinical isolates. In this study we extended our 
analysis of the B. pertussis population to genes that are involved in the 
regulation of virulence genes. No polymorphism was observed in the FHA 
promoter region, and only limited polymorphism in the bvgAS genes and the 
promoter regions of bvgAS and pertactin. However, a fair degree of 
polymorphism was observed in the promoter region of pertussis toxin (Ptx), 
ptxP. Eight alleles were observed in 6 different countries. In The Netherlands 2 
alleles were observed in recent clinical isolates. One of these, ptxP3, emerged in 
1993 and increased in frequency from 13% in 1996 to 85% in 2000, while the 
other, ptxP1 decreased in frequency. Comparison of Ptx production of ptxP1 and 
ptxP3 strains showed that ptxP3 strains produced more Ptx. Mice experiments 
showed that a ptxP3 strain induced higher leucocytosis and was better able to 
colonize compared to a ptxP1 strain, suggesting that ptxP3 strains cause more 
severe disease compared to ptxP1 strains. Strains, which cause more severe 
clinical symptoms, may show a higher transmission rate. We propose that 
vaccination may have selected for more virulent B. pertussis strains because of 
their improved transmissibility. 
 
A 
6   Promoter of Ptx 
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INTRODUCTION 
 
lthough vaccination against pertussis in The Netherlands was very effective 
during 45 years, B. pertussis is currently an endemic pathogen. Further, as 
in many other countries, a remarkable increase in the pertussis incidence was 
observed in The Netherlands in the 1990s, despite the fact that most children 
have been vaccinated (3;8;33;34;36;58). Several studies showed that the B. 
pertussis population changed after the introduction of vaccination. Antigenic 
divergence between vaccine strains and clinical isolates was observed. In the 
1990s, 90% of the clinical isolates contained novel, non-vaccine type, pertussis 
toxin and pertactin variants (19;56;59;82;88;92;157). Further, multi-locus 
sequence typing (MLST) revealed two MLST´s that were associated with 
epidemics. One of these MLST´s, MLST-5, which expanded remarkably in the 
years 1997 to 1999, was identical to a MLST, MLST-3, that declined in frequency 
in the same period, except for 1 silent mutation (154). Since it is very likely that 
this mutation is neutral, the distinctive behavior of MLST-3 and MLST-5 must be 
due to an as yet unidentified polymorphic locus, which has a strong affect on 
strain fitness.  
In this study, we extended our studies on polymorphism to genes that are 
involved in the regulation of the virulence genes of B. pertussis. The expression 
of the virulence genes in Bordetella is regulated by the bvgAS system (reviewed 
in (83)). This system mediates transition between the virulent Bvg+ phase and 
the avirulent Bvg- phase in response to particular environmental stimuli. In the 
Bvg+ phase, BvgS, the transmembrane sensory protein, becomes 
phosphorylated and a phosphate group is transferred to BvgA, the DNA binding 
protein. BvgA subsequently activates promoters of virulence genes (e.g. genes 
coding for filamentous hemagglutinin (FHA), pertactin (Prn) and pertussis toxin 
(Ptx)), while in the Bvg- phase the expression of these genes is down regulated. 
The sensing and regulation by this system might be affected by polymorphism in 
BvgS and/or BvgA, resulting in altered expression of virulence genes. Further, 
polymorphism in promoter regions of the virulence genes of B. pertussis might 
affect binding of BvgA and RNA polymerase, which in its turn may affect 
expression of virulence genes. 
A 
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Here, we analyzed polymorphism in bvgA and bvgS, and in the promoter regions 
of bvgAS (bvgP), FHA (fhaP), Prn (prnP) and Ptx (ptxP)(4;5;70;77). We 
observed significant polymorphism in the promoter region of Ptx (ptxP) and 
subsequently investigated its effect on expression of Ptx and on strain fitness in 
mice. Finally, we showed that a particular promoter variant is linked to MLST-5, 
which has expanded dramatically in recent years, explaining the distinct 
behaviors of MLST-3 and MLST-5. 
 
MATERIAL AND METHODS 
 
Bacterial strains 
B. pertussis strains were collected from 1949 to 2000. In total 493 isolates were 
included: 390 from The Netherlands, 10 from Australia, 49 from Finland, 11 
from Italy, 16 from Japan and 17 from The United States. The isolates were 
grown on Bordet Gengou agar (BG) supplemented with 1% glycerol and 4% 
sheep blood at 35oC for three days. 
 
Construction of isogenic strains 
Strain B1584, a streptomycin, kanamycin and nalidixin resistant derivative of 
Tohama, which harbors ptxP1, was used to construct a ptxP3 isogenic 
derivative. For this, a 414 bp large PCR fragment, containing ptxP3, was 
amplified with the primers ptxPBamH1F and ptxPEcoR1R and cloned into 
pSS1129 (129)(Table 1). The resulting plasmid p407ptxP3, was transformed 
into JM109 cells (Promega, USA) for amplification and subsequently transferred 
to E. coli SM10 (124), which allowed subsequent transfer to B. pertussis by 
conjugation. The plasmid pSS1129 is not able to replicate in B. pertussis, and 
selection for gentamycin resulted in the isolation of B. pertussis clones, in which 
p407ptxP was inserted into the B. pertussis chromosome by homologous 
recombination. Plating on media with streptomycin resulted in excision of 
p407ptxP, resulting in strains with ptxP1 or ptxP3. Strains with the ptxP3 allele 
were identified by sequencing, and one clone, B1880, was selected. 
6   Promoter of Ptx 
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Sequencing 
PCR amplification of chromosomal DNA was performed in 20 µl, containing 1 µl 
of DNA and 19 µl buffer comprising 50% HotstarTaq Master mix (Qiagen, 
Germany), 1 µM of each primer and 5% dimethyl sulfoxide as previously 
described (154). The primers used for amplification and sequencing of bvgA, 
bvgS, bvgP, fhaP, prnP and ptxP and the specific PCR conditions are shown in 
Table 1. Allele designation was based on the complete gene sequence, except 
for bvgS. The gene for bvgS was sequenced completely for 6 strains, while for 
the remaining 16 strains allele designation was based on the sequence of the 
polymorphic region (comprising bases 1-400). Sequence reactions were 
performed with an ABI Prism Big Dye terminator reaction kit and the reactions 
were analyzed with a model 377 or 3700 ABI DNA Sequencer (Perkin-Elmer 
Applied Biosystems). 
 
Western Blotting 
Cell-free lysates were prepared from bacterial cultures that were incubated for 
48 hrs on BG agar or 24 hrs in Thijs medium (139). Cell suspensions were 
adjusted to 4*109 cells (OD at 600 nm) or to 1 mg/ml protein (Pierce BCA-kit, 
Pierce, USA), and 5 µl was added to each slot. Samples were analyzed by 
electrophoresis using SDS-10% polyacrylamide gels. Electrophoretic transfer of 
proteins to Hybond-P+ membranes (Amersham Pharmacia biotech, USA) was 
accomplished by semi-dry blotting according to manufacturer’s instructions. 
After transfer of the proteins, the membranes were incubated overnight at 4oC 
or 1 h at RT in phosphate saline buffer (PBS) containing 0.5% non-fat dry milk, 
0.1% BSA and 0.1% tween 20. Subsequently, the membranes were incubated 
with monoclonal antibody Pem9 (a-PtxS1), P1 (a-PtxS1) or SU4 (a-PtxS4) 
diluted 1:1000 for 1h at RT. Membranes were washed 3 times for 5 min with 
PBS containing 0.1% tween 20 and subsequently incubated with alkaline 
phosphate (AP) labeled antimouse IgG for 1 h at RT. Membranes were 
developed with AP substrate after washing twice for 10 min with PBS containing 
0.1% tween 20. After 5 min membranes were scanned with a fluor imager (Fluor 
Imager 595, Molecular Dynamics, USA). Quantification of the amount of PtxS1 
6   Promoter of Ptx 
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was performed by calculating the area of a signal peak. PtxS1 expression by 
ptxP1 and ptxP3 strains was determined in 5 independent experiments. 
 
Mouse model 
Strains were flash-freezed and stored at –80oC, as previously described (155). 
The viability of the cell suspensions was determined prior to infection (155). For 
infection, BALB/c mice (Harlan, OlHsd) 4-5 weeks old, were lightly anaesthetized 
with ether and 20 µl of the inoculum was placed on top of each nostril and 
allowed to be inhaled. Five to eight mice per group were infected with either 
4*105 or 2*107 CFUs of strain B1584 (ptxP1) or B1880 (ptxP3). Non-infected 
mice served as controls. After 7 days mice were sacrificed by intraperitoneal 
injection of NembutalR (Sanofi/Algrin). Blood was collected by eye extraction in 
16 µl K3EDTA (Venoject, Belgium). Leucocyte counts were determined on a cell 
counter (Beckman Coulter, USA). For determination of CFUs, trachea and lungs 
were removed. The trachea was vortexed in 500 µl Verweij medium with 5 glass 
pearls for 30 sec at RT. The lungs were homogenized in 900 µl Verweij medium 
for 10 sec at 20,000 rpm with a blender (pro scientific, pro200) at RT. Finally, 
CFU appropriate dilutions were plated on BG plates supplemented with 
kanamycin, and the number of CFUs was determined after 3 days of incubation 
at 35oC. This experiment was performed 3 times. 
 
Statistical analysis 
Means and SEM were calculated of the leucocyte counts and the 10log CFU. 
Differences in expression of PtxS1, leucocyte counts and colonization were 
assessed by unpaired Student’s t-test. Significance was accepted at the p<0,05 
level, and all tests were two-tailed. 
 
RESULTS 
 
Polymorphism in regulatory genes 
We investigated polymorphism in 6 genes (Table 2). Each gene was sequenced 
completely for at least 6 strains, the two strains that are used for the Dutch 
WCV and 3 epidemiologically unrelated, recent, Dutch clinical isolates. Further, 
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Table 2. B. pertussis genes analyzed for polymorphisma. 
gene allele Number of strains frequency of 
alleles 
Accession number 
bvgA  6  M25401 
bvgS  22   
 bvgS1  95% (21) M25401 
 bvgS2  5% (1) this study 
bvgAS-P  6   
 bvgP1  83% (5) M25401 
 bvg-P2  17% (1) this study 
fhaP  6   
prnP  6   
 prnP1  83% (5) AJ006158 
 prnP2  17% (1) this study 
ptxP  493   
 ptxP1  63% (310) M13223 
 ptxP2  2% (12) this study 
 ptxP3  33% (163) this study 
 ptxP4  0.6% (3) this study 
 ptxP5  0.2% (1) this study 
 ptxP6  0.2% (1) this study 
 ptxP7  0.2% (1) this study 
 ptxP8  0.2% (1) this study 
a Allelic designation was based on the complete gene sequence, except for bvgS. The bvgS 
gene was sequenced completely for 6 strains, while for the remaining 16 strains the allelic 
designation was based on sequencing of the polymorphic region, comprising bases 1-400. 
 
we included strain 18323 in our analysis, which represents a distinct divergent 
branch in the phylogenetic tree of B. pertussis (96;150). Subsequently, the 
analysis of one gene, ptxP, which showed substantial polymorphism in the Dutch 
B. pertussis population, was extended to strains from Australia, Finland, Italy, 
Japan and The United States. 
No polymorphism was observed in bvgA and fhaP. For bvgP and the upstream 
region of prn, polymorphism was only observed relative to strain 18323 (Fig. 1). 
Strain 18323 contained one base substitution relative to all other strains 
analyzed. The promoter region of bvgAS (bvgP) contains 4 promoters, P1-4, and 
the polymorphic site was found near the –35 box of P2 (118;119).  
The polymorphic site in prnP was located 38 bases downstream the start site for 
transcription and 113 bases upstream of the initiation codon of prn (70). We 
6   Promoter of Ptx 
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Fig. 1. Alleles of 
bvgS, and the 
promoter regions 
for bvgAS (bvgP) 
and prn (prnP), 
respectively (70; 
118;119). Dots 
indicate identity. 
Numbers refer to 
the underlined 
base. Numbering 
of bvgS is 
relative to the A 
of the initiation codon, while numbering of the promoter sequences is relative to start of 
transcription. For prnP the initiation codon has been indicated. 
 
observed two alleles for bvgS in Dutch B. pertussis strains one of which, bvgS2, 
was observed in one clinical isolate only (n= 22) (Fig. 1). Polymorphism in the 
abovementioned genes was not analyzed further, because of the low degree of 
variation observed. 
For ptxP, in total 8 alleles were found: ptxP1-8 (Fig. 2). Compared to ptxP1, the 
alleles ptxP2, ptxP3, ptxP5, ptxP6 ptxP7 and ptxP8 each contained 1 
polymorphic site, while ptxP4 harbored 8 polymorphic sites. The polymorphic 
sites of ptxP2, ptxP5, ptxP6 and ptxP7 were found near or at the BvgA binding 
site (Fig. 2). The polymorphic sites of ptxP3 and ptxP8 were found near or at the 
RNA polymerase binding site, while the polymorphic sites in ptxP4 were found in 
the whole promoter region (77;80). 
 
Temporal trends in frequencies of ptxP alleles in The Netherlands 
The availability of an extensive, well-defined, strain collection allowed a detailed 
analysis of temporal trends in the frequencies of the ptxP alleles in The 
Netherlands. Analysis of 390 Dutch isolates revealed the presence of the alleles 
ptxP1, ptxP2, ptxP3, ptxP4, ptxP6 and ptxP7 (Fig. 2). To study temporal trends, 
  364 
bvgS1  GGG CAG ATC GAC CTC 
    G   Q   I   D   L 
bvgS2  ... ... .C. ... ... 
    .   .   T   .   . 
 
        -41    -35box    -10box of P2 
bvgP1  CCAGCGCAGGAATTCAGA-//-TAGGAT 
bvgP2  .......G..........-//-...... 
 
   -35 box   -10 box    +1            +38       +151 
prnP1  TTGCTTA-//-GAGAAT-//-CTG-//-GACAAATACCGTGC-//-ATG 
prnP2  .......-//-......-//-...-//-........G.....-//-... 
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Fig. 3. Temporal trends in frequencies of ptxP alleles in The Netherlands in the period 
1949-2000. N indicates number of isolates. 
 
strains were stratified in the periods 1949-1954, 1965-1980, 1981-1985, 1986-
1990, 1991-1995 and 1996-2000 (Fig. 3). The alleles ptxP1 and ptxP2 were 
present in the 2 strains used to produce the Dutch WCV and were found in, 
respectively, 50% and 45% of the strains from the period 1949-1954. One 
isolate from this period contained ptxP4 (5%). In the period 1965-1980 2 alleles 
were observed, ptxP1 and ptxP6, with frequencies of 93% and 7%, respectively. 
In the 2 subsequent periods, 1981-1985 and 1986-1990, only ptxP1 was 
observed. In the period 1991-1995 ptxP1, ptxP3, ptxP2 and ptxP7 were found at 
frequencies of 73%, 24%, 2% and 2%, respectively. In the period 1996-2000 
the frequency of ptxP3 increased to 52%, while ptxP1 was found in 48% of the 
isolates. 
In 1996 a severe pertussis epidemic occurred in The Netherlands and the 
incidence has remained high since (33;34). Therefore the period 1990-2000 was 
studied in more detail by stratifying strains in smaller periods (Fig. 4). Data from 
the years 1990-1992 were pooled, because of the low numbers of isolates 
available. In the period 1990-1992 ptxP1, ptxP2 and ptxP7 were found with 
frequencies of 88%, 6%, and 6%, respectively. The ptxP3 allele was first 
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observed in 1993 and found in 21% of the isolates. The ptxP3 allele increased in 
frequency to 41% in 1995, followed by a drop to 13% in 1996. In the 
subsequent years a remarkable expansion of ptxP3 strains was observed. The 
ptxP3 allele was found in 33% of the strains in 1997 and strains with ptxP3 
expanded to frequencies of 56%, 67% and 85% in 1998, 1999 and 2000, 
respectively. 
Fig. 4. Temporal trends in frequencies of ptxP alleles in The Netherlands in the period 
1990-2000. Data from the years 1990-1992 were pooled, due to low number of isolates. N 
indicates number of isolates. 
 
Global distribution of ptxP alleles 
For a comparison of the global distribution of ptxP alleles, isolates from the 
period 1990-2000 from Australia, Finland, Italy, Japan, The Netherlands and The 
United States, were compared (Table 3). From The Netherlands and The United 
States, isolates from the prevaccination period were also included. In this 
period, the alleles ptxP1, ptxP2 and ptxP4 were found at frequencies of 43%, 
29% and 29% in The United States, compared to 50%, 45% and 5% in The 
Netherlands. In the period 1990-2000, the allele ptxP1 was found in all countries 
investigated. However, it was observed in much higher frequencies (81%-98%) 
in Australia, Finland, Italy and Japan, compared to The Netherlands and the 
United States, where it was found at frequencies of 53% and 30%, respectively.  
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In this period ptxP3 was observed in all countries, except Italy. High frequencies 
of this allele were only observed in The Netherlands and the United States (46% 
and 70%, respectively). Finally, the alleles ptxP5, ptxP7 and ptxP8 were found in 
single isolates in Italy, The Netherlands and Japan, respectively. 
 
Effect of polymorphism in ptxP on expression of PtxS1 
In order to determine the effect of the polymorphism in ptxP on expression of 
Ptx cell-free extracts of clinical isolates that contain ptxP1, ptxP2 or ptxP3 (the 
ptxP alleles that were observed relatively frequently) were examined by Western 
blot analysis (Fig. 5). 
The membranes were incubated with a monoclonal antibody directed against 
PtxS1, Pem9 and PtxS1 expression was quantified by densitometry. For ptxP1, 
ptxP2 and ptxP3, 3 clinical isolates were examined. The average signal of the 
ptxP1 isolates was adjusted at 100%. The ptxP2 isolates produced 61% PtxS1 
relative to ptxP1 strains (P=0.104), while ptxP3 isolates produced 208% PtxS1 
relative to ptxP1 strains (P=0.002). This experiment was repeated 5 times and 
PtxS1 expression of ptxP3 relative to ptxP1 strains varied between 130% to 
208%. 
 
Fig. 5. The effect of polymorphism in ptxP on expression of pertussis toxin. Equal amounts 
of strains were analyzed by Western blotting using a monoclonal antibody against PtxS1. 
Expression of PtxS1 was quantified by densitometry, and the average PtxS1 expression of 
ptxP1 strains was adjusted to 100%. Average of PtxS1 expression of ptxP2 and ptxP3 
strains relative to ptxP1 strains is shown. SEM of the ptxP1, ptxP2 and ptxP3 is shown. The 
ptxP and ptxS1 alleles harbored by the strains are indicated above the lanes. 
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Monoclonal antibody Pem9 bound to PtxS1, the subunit of Ptx that contains 
several polymorphic sites (92). The 3 ptxP1 strains expressed either PtxS1A or 
PtxS1B, while the ptxP2 and ptxP3 strains expressed PtxS1D and PtxS1A, 
respectively (Fig. 5). Therefore, it was possible that the Western blot results 
were affected by differential binding of Pem9 to PtxS1. To investigate this, 
Western blots were also performed with another monoclonal antibody against 
PtxS1 (designated P1) and a monoclonal antibody directed against PtxS4, which 
is monomorphic (designated SU4). For P1 and SU4 similar results as for Pem9 
were found (data not shown).  
 
Effect of variation in ptxP on colonization and leucocytosis  
Mice were infected with the isogenic strains, B1584 (ptxP1) or B1880 (ptxP3) 
with either 5*104 or 2*107 CFU. The ability of these strains to colonize trachea 
and lungs and cause leucocytosis was determined 7 days after infection.  
At the low dose, B1880 (ptxP3) colonized the trachea and lungs of mice 
significantly better compared to B1584 (ptxP1)(p=0.002 and p=0.005, 
respectively)(Fig. 6). At the high dose, no significant difference in colonization 
was observed (Fig. 6).  
 
Fig. 6. Effect of polymorphism in ptxP on colonization of mice. Mice were infected with 
5*104  or 2*107 CFUs of B1584 (ptxP1) and B1880 (ptxP3) and colonization of trachea and 
lungs was determined 7 days after infection. The line indicates the median. P-values are 
shown. This experiment was performed three times and a representative result is shown. 
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Fig. 7. Effect of 
polymorphism in ptxP 
on leucocyte counts 
in mice. Mice were 
infected with 5*104  
or 2*107 CFUs of 
B1584 (ptxP1) and 
B1880 (ptxP3). 
Leucocyte counts 
were determined 7 
days after infection. 
The line indicates the 
median. P-values are shown. This experiment was performed three times and a 
representative result was shown. 
 
At the low dose, leucocyte counts of B1584 (ptxP1) and B1880 (ptxP3) infected 
mice were not different (p=0.747) (Fig. 7). Although leucocyte counts of mice 
that were infected with the low dose of B1584 (ptxP1) or B1880 (ptxP3) were 
higher than those of control mice, the difference was not significant (p=0.970). 
At the high dose, B1880 (ptxP3) infected mice showed higher leucocyte counts 
compared to B1584 (ptxP1) infected mice (p=0.072) (Fig. 7). Interestingly, with 
the high dose B1880 (ptxP3) infected mice showed symptoms of discomfort: 
they were less alert, ate less and had an unkempt appearance. In contrast, mice 
that were infected with the same dosage of B1584 (ptxP1) did not show these 
clinical signs. 
  
DISCUSSION 
 
To address the hypothesis that adaptation of B. pertussis to vaccination might 
be a cause for the re-emergence of pertussis, we previously studied 
polymorphism in genes coding for surface proteins (3;8;33;34;36;58). We 
observed variation in a limited number of surface proteins and divergence 
between vaccine strains and modern clinical isolates (19;56;59;82;88;92;157). 
In this study we extended our analysis of polymorphism in B. pertussis to genes 
that are involved in regulation of expression of virulence factors.  
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In B. pertussis the expression of virulence genes is regulated by the BvgAS 
system, which showed only limited polymorphism, however. Polymorphism was 
observed in bvgS that occurred as 2 alleles in Dutch B. pertussis strains. The 
mutation in bvgS was non-silent and was located in the environmental sensing 
domain (143). The Bvg- phase has been suggested to be important for survival 
of the animal pathogen Bordetella bronchiseptica outside its host (81). Since B. 
pertussis is a strictly human pathogen with no known environmental niche, the 
function of the Bvg- phase in B. pertussis is unknown and it might be an 
evolutionary remnant. Although the role of the Bvg- phase for B. pertussis is not 
clear, an intermediate phase, Bvgi phase, has recently been identified that might 
be important for colonization of the nasopharynx, where conditions may be 
intermediate between those inducing the Bvg- and Bvg+ phase (28;38). Since 
there was no expansion of strains with bvgS2, it is less likely that this allele is 
beneficial for the bacterium. Alternatively, this allele might be linked to other; as 
yet unknown, polymorphic sites that affect strain fitness negatively. 
No polymorphism was observed in the FHA promoter region. Polymorphism in 
bvgP and prnP was observed relative to strain 18323, only. The upstream region 
of bvgAS contains 4 promoters (P1-4) and the polymorphic site was located near 
the –35 box of P2 (118;119). Thus it is conceivable that variation in this site 
affects transcription of bvgAS. The polymorphic site in the promoter region of 
prn was located 38 bases downstream the start site for transcription and 113 
bases upstream of the initiation codon (70). Thus it is unlikely that the 
polymorphism affects transcription or translation. 
A remarkable degree of polymorphism was observed in the promoter region of 
Ptx. In contrast to Nygren et al., who did not observe variation in ptxP in 
Swedish strains (n=11), we observed 8 different ptxP alleles in 6 countries 
(103). Three ptxP alleles, ptxP1, ptxP2 and ptxP3, were observed with relative 
high frequencies. In The Netherlands and The United States ptxP1, ptxP2 and 
ptxP4 were observed in the prevaccination period (Table 3). In recent clinical 
isolates, two alleles ptxP1 and ptxP3 were frequently observed. Strains with 
ptxP3 occurred in high frequencies in The Netherlands and The United States 
(respectively, 46% and 70% in the period 1990-2000), two countries that have 
reported an increased pertussis incidence (8;33;34;58). However, in Australia, a 
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country that also showed an increased pertussis incidence, ptxP3 strains were 
found with a frequency of 10% only, while ptxP1 dominated (3). 
Previously, we identified two multi-locus sequence types (MLST’s) that were 
associated with countries that experienced an increased pertussis incidence; 
MLST-4 and MLST-5 (154). MLST-5 expanded remarkably in the years 1997-
1999 in The Netherlands and predominated in The United States in the period 
1990-2000 (154). MLST-5, however, differed only in a neutral mutation in ptxS3 
from MLST-3, which declined in frequency in the same period. We found that 
ptxP3 was linked to ptxS3B, harbored by MLST-5 strains, in all isolates tested. 
In contrast, MLST-3, harboring ptxS3A, was linked to ptxP1. We propose that 
the distinctive behavior of MLST-3 and MLST-5 is caused by the linkage to ptxP1 
and ptxP3, respectively (see below). 
The polymorphic locus of ptxP3 was located near the RNA polymerase binding 
site (77;80) and affected the expression of PtxS1. We found that ptxP3 isolates 
produced (130% to 208%) more PtxS1 compared to ptxP1 isolates. Since the 
amount of PtxS1 reflects the amount of Ptx produced (102), ptxP3 strains 
produce more Ptx. Ptx is an ADP ribosyltransferase, which blocks the GTPase 
regulated pathways, resulting in tissue specific effects, such as hypoglyceamia 
and leucocytosis in humans and leucocytosis, hyperinsulinaemia, IL4 and IgE 
secretion in mice (93;106;140). We hypothesized that strains, which express 
more Ptx, cause more severe pertussis.  
To address this hypothesis, we used a mouse model. Mice were intranasally 
infected with equal amounts of isogenic strains carrying ptxP1 or ptxP3, and 
virulence was determined by measuring leucocytosis and colonization. We found 
more pronounced leucocytosis in mice that were infected with the ptxP3 strain. 
In human infants severity of pertussis infection was correlated with extreme 
leucocytosis. Pierce et al. found significant higher leucocytosis in children, who 
did not survive a B. pertussis infection, compared to children, who survived the 
infection (105). Thus, these data indicate that ptxP3 strains may cause more 
severe disease relative to ptxP1 strains. Further, we found that the colonization 
ability of the ptxP3 strain was increased relative to the ptxP1 strain. These data 
are consistent with those of Kinnear et al, who challenged mice with inocula that 
contained various amounts of purified Ptx and found that colonization increased 
6   Promoter of Ptx 
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with the amount of Ptx added (71). These data suggest that pertussis toxin is 
advantageous for survival in the host.  
In the UK severity of pertussis disease has been associated with the expression 
of particular serotypes. Clinical isolates that expressed fimbrial serotype 2 (st2), 
which frequency increased in the period 1995-1997, were associated with more 
severe pertussis (146). It would be interesting to investigate if the British strains 
also harbor ptxP3. However, in The Netherlands ptxP3 was found in 152 st3 
strains and only in 2 st2 strains. 
Epidemiological data also support the observations that ptxP3 strains cause 
more serious disease. An increase in number of deaths due to pertussis was 
observed since 1996. 
In the period 1996-
1999 8 deaths due to 
pertussis were 
observed, compared to 
0, 1, 0, 0 and 2 deaths 
in the periods 1976-
1979, 1980-1983, 
1984-1987, 1988-1991 
and 1992-1995 (Fig. 
8).  
Calculation of lethality 
(number of deaths / 
number of hospital ad-
missions) also showed 
 
Fig. 8. Deaths due to 
pertussis and ptxP3 
frequency in the period 
1976-1999. The bars 
show the ptxP3 frequency. (A) The line shows the cumulative number of deaths per period 
of 4 years. (B) The line shows pertussis lethality (number of deaths due to pertussis / 
hospital admissions) per period of 4 years. 
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an increase from 0.0000, 0.0022, 0,0000, 0.0000 and 0.0024 in the periods 
1976-1979, 1980-1983, 1984-1987, 1988-1991 and 1992-1995 to 0.0046 in the 
period 1996-1999 (Fig. 8). Eighty-eight percent of the deaths due to pertussis 
are observed in children < 3 months, the unimmunized group. Gandon et al. 
showed in a mathematical model that some type of vaccines may select for 
more virulent strains (50). Expansion of such strains result in an increased 
mortality in naive individuals. More severe clinical symptoms, especially 
coughing, are beneficial for transmission of B. pertussis. Further, transmission 
may increase due to the better colonization ability of ptxP3 strains. We propose 
that increased Ptx production may increase transmission by enhancing 
colonization and clinical symptoms like coughing. The enhanced clinical 
symptoms may affect mortality.  
The novel ptxP3 allele may affect vaccine efficacy of WCVs and ACVs in several 
ways. First, increased Ptx production may accelerate the onset of clinical 
symptoms and hence the transmission to the next host, leaving the (primed) 
immune system less time to react. Second, higher titers of (pre-)existing 
antibodies may be required to neutralize Ptx. In this regard, the higher levels of 
Ptx antibodies induced by ACVs compared to WCVs might be beneficial (37). Ptx 
antibodies play an important role in immunity against clinical symptoms and 
inhibition of transmission. A recent report of Taranger et al. observed a decline 
in spread of B. pertussis in a population that recently has been vaccinated with a 
monocomponent pertussis toxoid ACV (135). Further, Alonso et al. suggested 
that the presence of (inactive) Ptx on the surface of the bacterium is a direct 
target for the immune system of the host (1), suggesting that ptxP3 strains 
would be more immunogenic in immunized individuals and thus less well able to 
survive. We are currently investigating the effect of polymorphism in ptxP on 
immunity. 
Bordetella pertussis is one of the most contagious pathogens. We propose that 
vaccination has reduced the transmission rate of B. pertussis, and selected for 
strains with increased transmission rates. As transmission is coupled to clinical 
symptoms, such strains are more virulent. Here, we showed that fifty years after 
the introduction of vaccination the current circulating strain may have adapted 
to vaccination by increasing its transmissibility.  
6   Promoter of Ptx 
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hooping cough or pertussis is a highly contagious disease of the 
respiratory tract, caused by Bordetella pertussis. In the prevaccination 
period almost every child contracted pertussis. The clinical course is most severe 
in neonates and infants and most hospitalized cases are children < 2-3 months 
of age, the age group that is too young to be vaccinated. Although viewed as a 
childhood disease, pertussis is now recognized as an important infectious 
disease in adults (17;58;122;132), who represent a reservoir for transmission to 
susceptible (unimmunized) children (10;78;160).  
In The Netherlands mass vaccination against B. pertussis was introduced in 
1953 and was very effective in reducing the pertussis incidence and mortality 
(25). Although vaccination was initially very effective, the pertussis incidence 
increased remarkably after 1996 in The Netherlands. Epidemics have been 
reported in 1996, 1999 and 2001, while in the intermittent years the incidence 
did not return to levels observed previous to 1996 (33;34). Increased pertussis 
incidences were also observed in other countries with a high vaccination 
coverage, such as Australia, Canada, Poland and The United States 
(3;8;36;58;59). The goal of this thesis was to find an explanation for the re-
emergence of B. pertussis in countries with highly vaccinated populations, in 
particular The Netherlands. 
 
The re-emergence of pertussis might be explained by changes in surveillance 
and diagnostic criteria, changes in vaccine quality or a decrease in vaccine 
coverage. However, for The Netherlands these possibilities have been excluded 
(33). Waning vaccine-induced immunity and strain adaptations are other 
possible explanations. Indeed, we observed that the introduction of vaccination 
affected the B. pertussis population significantly (chapter 2, 3 and 4). Notable 
changes were observed in the population structure of Dutch B. pertussis strains 
in 2 periods: the 1960s, a decade after the introduction of vaccination and in the 
1990s, the period, when pertussis re-emerged in The Netherlands (chapters 2 
and 4). IS1002-based fingerprint typing showed a change in fingerprint types a 
decade after the introduction of vaccination. Fingerprint types from the 
prevaccination period disappeared, while novel fingerprint types emerged. In 
particular the frequency of one fingerprint type, ft 29, increased remarkably 
W
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from 0% in the 1950s (the prevaccination period) to 50% in the 1960s. These 
changes were reflected in the genotypic diversity, which was 0.9 in the 
prevaccination period and decreased to 0.6 in the 1960s (chapters 2 and 4)(Fig. 
1).  
Fig. 1. Correlation between genotypic diversity and the emergence of novel alleles of 
ptxS1, prn, tcfA and ptxP. The line and bars represent the genotypic diversity and novel 
alleles, respectively. The novel alleles are distinct from those found in the vaccine strains. 
 
We hypothesized that antigenic divergence between vaccine strains and 
circulating strains may be the underlying cause of the changes observed with 
IS1002 fingerprint typing. To address this hypothesis, we studied polymorphism 
in genes coding for surface proteins (chapter 3 and 4). In the 1960s the only 
mismatch we detected between the vaccine strains and circulating strains was 
with respect to PtxS1. The observed decrease in genotypic diversity in this 
period was found to be associated with expansion of strains with the ptxS1A 
allele, which was distinct from the alleles found in the vaccine strains (ptxS1B 
and ptxS1D)(Fig. 1). Although we observed divergence between vaccine strains 
and clinical isolates, suggesting that vaccination selected for strains that were 
less affected by vaccine-induced immunity, vaccination remained very effective, 
since mortality decreased 543-fold in the late 1960s compared to the 
prevaccination period (25). 
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The second period showing changes in the population structure was observed in 
the 1990s. In this period we observed divergence between vaccine strains and 
clinical isolates in the surface associated proteins pertactin (Prn) and tracheal 
colonization factor (TcfA)(chapter 3)(92). For TcfA, the vaccine type, TcfA2, was 
replaced by the novel variant TcfA3, while for Prn, the vaccine types Prn1 and 
Prn7, were replaced by Prn2 and Prn3. Polymorphism was not restricted to 
genes coding for surface proteins, but was also observed in regulatory genes, 
such as the promoter region for pertussis toxin, ptxP (chapter 6). The alleles 
ptxP1 and ptxP2, found in the vaccine strains, were replaced by ptxP3 in the 
1990s (Fig. 2).  
Fig. 2. Pertussis notifications (A) and the frequencies of novel alleles for tcfA and ptxP (B, 
C). 
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In The Netherlands the pertussis incidence increased after 1996 (Fig. 2). 
However, comparison of the periods before and after 1996 did not reveal 
significant differences in fingerprint types and frequencies of alleles (chapter 2 
and 3).  
A detailed analysis of the period 1990-2000 did reveal interesting trends in 
frequencies of the polymorphic proteins TcfA and Prn (Fig. 2). The twofold 
increase in notifications in 1994 compared to 1993 and the 10-fold increase in 
notifications in 1996 compared to 1995 was associated with an increase in 
frequency of strains harboring the non-vaccine type variant TcfA3. Thus, the 
observed increase in notifications may have been caused by a change in the B. 
pertussis population. This assumption is consistent with results from 
mathematical modeling performed by Boven et al., which suggested that the 
most likely cause for the 1996 epidemic was a change in the B. pertussis 
population (145). After 1996 strains with the tcfA3 allele decreased in 
frequency. This may have been caused by the naturally induced immunity 
against TcfA3 strains. 
In 1998 and 1999 there was a substantial increase in notifications compared to 
1997 (1,9 and 3,2 fold, respectively). This increase was associated with 
expansion of strains harboring the ptxP3 allele, again suggesting that epidemic 
years are associated with clonal expansion of particular strains (chapter 6). 
The number of deaths due to pertussis has increased since 1996. In the period 
1996-1999, 8 deaths due to pertussis were observed compared to 0, 1, 0, 0 and 
2 deaths, respectively, in the periods 1976-1979, 1980-1983, 1984-1987, 1988-
1991 and 1992-1995 (Fig. 3). As 88% of the deaths were children < 3 months, 
this suggests an increased number of deaths in unimmunized individuals. 
Gandon et al. showed in a mathematical model that some types of vaccines may 
select for more virulent strains (50). Expansion of such strains caused higher 
mortality rates in unimmunized individuals.  
Calculation of lethality (number of deaths / number of hospital admissions) also 
showed an increase from 0.0000, 0.0022, 0.0000, 0.0000 and 0.0024 in the 
periods 1976-1979, 1980-1983, 1984-1987, 1988-1991 and 1992-1995, 
respectively, to 0.0046 in the period 1996-1999 (Fig. 3). The increase in 
lethality coincided with an increase in the frequency of strains with ptxP3, 
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suggesting that ptxP3 strains may cause more severe disease due to increased 
Ptx production  (chapter 6). Animal studies showed that leucocyte counts of 
mice infected with a ptxP3 strain were significantly higher compared to those of 
ptxP1 infected mice (chapter 6). In human infants the level of leucocytosis was 
correlated with severity of infection and lethality (105). More severe clinical 
symptoms, especially 
coughing, are beneficial for 
transmission of B. 
pertussis. Further, 
transmission may increase 
due to the better 
colonization ability of ptxP3 
strains (chapter 6). We 
propose that increased Ptx 
production may be bene-
ficial for transmission by 
enhancing clinical symp-
toms and colonization. 
Both factors may affect 
mortality. 
 
Fig. 3. Deaths due to 
pertussis and ptxP3 frequency 
in the period 1976-1999. The 
bars show the ptxP3 frequency. (A) The line shows the cumulative number of deaths per 
period of 4 years. (B) The line shows pertussis lethality (number of deaths due to pertussis 
/ hospital admissions) per period of 4 years. 
 
We observed a non-random association between prn alleles and alleles of other 
polymorphic genes; e.g. tcfA3 was linked with prn3 and ptxP3 with prn2 
(chapter 3). This was unexpected, as variation in Prn is based on recombination 
within the repeated region or slipped strand mispairing, phenomena, which 
occur at relatively high frequency and are reversible. Gupta et al. have shown 
that pathogen populations may segregate into discrete strains with non-
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overlapping antigenic structures, if these structures are immunodominant (57). 
The non-random distribution of prn alleles may reflect strong immune selection 
focused on Prn, TcfA and other, as yet unknown, B. pertussis antigens.  
Several observations underline the importance of Prn, TcfA and Ptx in immunity. 
Sero-epidemiological studies have shown a correlation between the titer of anti-
Prn antibodies and clinical protection (23;131;131). Vaccination with a 
monocomponent pertussis toxoid vaccine-induced significant protection for at 
least 2 years and decreased the spread of B. pertussis in a population 
(135;135;136). Intranasal vaccination of mice with an attenuated Vibrio 
Cholerae strain expressing TcfA resulted in significant reduction of colonization 
of the trachea (22). The fact that the polymorphic sites in Ptx and Prn comprise 
B- and T-cell epitopes indicate that these sites are immunologically relevant 
(21;30;69;120). Finally, variation in Prn was shown to affect the efficacy of a 
whole cell pertussis vaccine in a mouse model (69). Protection was best against 
Prn1, the vaccine type Prn, and lower against Prn2 and Prn3. We observed that 
strains carrying non-vaccine types Prn and PtxS1 are less well able to colonize 
naive mice compared to those carrying vaccine types (chapter 5), explaining the 
absence of the non-vaccine types in the prevaccination period (92). These data 
indicate that vaccination has shifted the competitive balance between strains, 
resulting in expansion of strains that are less fit in unimmunized individuals. 
The next question to address is how to control pathogens with polymorphic 
antigens, such as B. pertussis. Mathematical modeling emphasizes the 
importance of developing vaccines against a set of conserved antigens, even if 
these are less immunogenic (2). We identified a number of conserved antigens, 
such as BrkA, FHA, Fimbriae, OmpP, OmpQ and Vag8, which may be included in 
future vaccines (chapter 3). Because of the importance in immunity against B. 
pertussis the polymorphic proteins TcfA and Prn may be potential vaccine 
components, especially when the immune response is directed to conserved 
epitopes to avoid the emergence of escape variants.  
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The data presented in this thesis provide an explanation for the re-emergence of 
pertussis and a better understanding of how pathogens evolve after the 
introduction of vaccines. We show that vaccination may result in the emergence 
of more virulent strains. This knowledge may contribute to the development of 
better pertussis vaccines. 
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inkhoest is een ernstige infectie aan de bovenste luchtwegen, veroorzaakt 
door de bacterie Bordetella pertussis. Kinkhoest was in het begin van de 
20e eeuw een van de meest voorkomende kinderziekten, totdat er in de 50er 
jaren grootschalige vaccinatie werd ingevoerd. Kinkhoest verloopt het meest 
ernstig in pasgeborenen en kinderen jonger dan 1 jaar. In de kinderleeftijd heeft 
de ziekte een karakteristiek beloop. In het begin kenmerkt de ziekte zich door 
algemene symptomen van verkoudheid en koorts, gevolgd door een fase, waarin 
de kenmerkende “kinkende” hoest zich presenteert, een periode die enkele 
weken tot maanden kan duren. Pasgeborenen en kleine kinderen kunnen in deze 
fase ernstig ziek worden a.g.v. ademhalingsmoeilijkheden, die ontstaan omdat 
zij het taaie slijm niet kunnen ophoesten, soms met de dood tot gevolg. 
Recentelijk is echter gevonden dat kinkhoest ook veel voorkomt bij volwassen, 
die de ziekte kunnen overdragen op (niet-immune) kinderen. 
De vaccins, die in de 50er jaren geïntroduceerd zijn, bestonden uit hele gedode 
bacteriën (in Nederland onderdeel van het DKTP vaccin) en waren zeer effectief 
in het bestrijden van de ziekte. In de 70er jaren zorgde negatieve publiciteit 
over de bijwerkingen van het kinkhoestvaccin voor de ontwikkeling van nieuwe 
vaccins. Deze acellulaire vaccins bestaan uit een aantal immunogene 
bestanddelen van de bacterie en geven minder bijwerkingen. In veel landen zijn 
de hele cel vaccins door deze nieuwe acellulaire vaccins vervangen. In 
Nederland wordt nog steeds het hele cel vaccin uit de jaren 50 gebruikt. 
Ondanks de hoge vaccinatiegraad in Nederland is het aantal kinkhoestgevallen 
enorm toegenomen sinds 1996 met epidemieën in 1996, 1999 en 2001 (Fig. 1. 
p.13). In Nederland nam vooral het aantal kinkhoestpatiënten toe in de 
leeftijdsgroepen 1-4 jaar en 5-9 jaar. Om deze kinderen beter te beschermen 
zijn de DKTP vaccinaties met 1 maand vervroegd (van 3, 4, 5 en 12 naar 2, 3, 4 
en 11 maanden) en worden kinderen van 4 jaar sinds 2001 gevaccineerd met 
een acellulair vaccin. Het is echter niet duidelijk waarom het aantal kinkhoest 
gevallen zo is toegenomen. Het doel van dit proefschrift was om een verklaring 
te vinden voor de toegenomen kinkhoest incidentie in landen met een hoge 
vaccinatiegraad, Nederland in het bijzonder. 
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Er zijn een aantal oorzaken waarom de incidentie van kinkhoest zou kunnen 
toenemen, zoals veranderingen in de surveillance en diagnostiek, veranderingen 
in de vaccinproductie en een verlaging van de vaccinatiegraad. Deze 
verklaringen kunnen echter de toename in incidentie in Nederland niet 
verklaren. Een van de factoren die verder van belang is, is het feit dat de 
bacterie zich aangepast kan hebben aan het vaccin. 
Om dit te kunnen onderzoeken hebben wij bacteriestammen bestudeerd, die bij 
patiënten zijn geïsoleerd in de periode 1949-2000, en deze vergeleken met de 
stammen, die voor het vaccin gebruikt worden. In dit proefschrift wordt 
aangetoond dat er grote veranderingen in de B. pertussis populatie zijn ontstaan 
na de introductie van vaccinatie. Opmerkelijke verschillen werden gevonden in 2 
perioden: de jaren 60, 10 jaar na de introductie van vaccinatie, en de jaren 90, 
de periode waarin de kinkhoestincidentie in Nederland weer is toegenomen 
(hoofdstukken 2 en 4). 
 
M.b.v. IS1002 fingerprint typering werden grote verschillen gevonden in 
fingerprint types in de jaren 60. Tien jaar na de start van vaccinatie verdwenen 
de fingerprint types uit de prevaccinatieperiode en werden nieuwe fingerprint 
types gevonden. Met name de frequentie van 1 fingerprint  type (ft 29) nam toe, 
tot 50% van de isolaten uit de 60er jaren. A.g.v. de opkomst van nieuwe 
fingerprint types nam de genetische diversiteit af in de jaren 60 (Fig. 1. p. 122).  
Omdat variatie in buitenmembraaneiwitten (antigene variatie) de onderliggende 
oorzaak kan zijn van de opkomst van bepaalde fingerprint typen, onderzochten 
wij variatie in genen, die coderen voor deze buitenmembraaneiwitten. Het enige 
eiwit dat variatie vertoonde tussen vaccinstammen en klinisch isolaten in de 
jaren 60 was subeenheid 1 van pertussis toxine (PtxS1). Het nieuwe type, 
ptxS1A werd in 50% van de stammen gevonden, terwijl de frequentie van de 
vaccin types ptxS1B en ptxS1D afnam. Ondanks dat er antigene variatie werd 
gevonden in vaccinstammen en klinisch isolaten, hetgeen suggereert dat 
vaccinatie heeft geselecteerd voor stammen waarop vaccin geïnduceerde 
immuniteit minder effect heeft, was vaccinatie in de jaren 60 erg effectief, 
aangezien het sterftecijfer een 543-voudige daling vertoonde t.o.v. de 
prevaccinatieperiode. 
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De 2e periode, waarin grote verschillen in de B. pertussis populatie werd 
gevonden is de jaren 90. In deze periode werd er variatie gevonden in 2 
buitenmembraan geassocieerde eiwitten, pertactine (Prn) en tracheaal 
kolonisatie factor (TcfA). Voor Prn zijn de vaccintypes Prn1 en Prn7, vervangen 
door Prn2 en Prn3. Voor TcfA is het vaccintype TcfA2 vervangen door TcfA3 
(hoofdstuk 3). Verder is er variatie gevonden in genen, die betrokken zijn bij 
regulatie van expressie van eiwitten, o.a. de promoter regio van pertussis toxine 
(ptxP). De vaccintypes ptxP1 en ptxP2 zijn vervangen door ptxP3 (hoofdstuk 6).  
In Nederland is er een toename van kinkhoestpatiënten geregistreerd sinds 
1996. Vergelijking van de perioden voor en na 1996 leverde echter geen 
verschillen op in fingerprint types en frequenties van allelen. 
Een meer gedetailleerde analyse van de periode 1990-2000 leverde interessante 
trends op in frequenties van allelen van de polymorfe eiwitten (Fig. 2. p.123). 
De 2-voudige toename in kinkhoestaangiften in 1994 t.o.v. 1993 en de 10-
voudige toename in 1996 t.o.v. 1995 was geassocieerd met een toename in 
frequentie van stammen met het niet-vaccintype TcfA3. Dus, de toename in 
incidentie kan verklaard worden door verandering in de B. pertussis populatie. 
Deze aanname komt overeen met mathematische modellering van Boven et al., 
die suggereert dat de toename in incidentie verklaard kan worden door een 
veranderde B. pertussis populatie. Na 1996 nam de frequentie van stammen 
met TcfA3 af, hetgeen verklaard kan worden door de toename in immuniteit 
tegen deze stammen. 
In 1998 en 1999 was er een toename in aangiften t.o.v. 1997 (1,9 en 3,2 x, 
respectievelijk)(Fig. 2. p.123). Deze toename is geassocieerd met de toename in 
frequentie van ptxP3 stammen, opnieuw suggererend dat epidemische jaren zijn 
geassocieerd met clonale expansie van bepaalde stammen (hoofdstuk 6). 
Het aantal doden t.g.v. kinkhoest is sinds 1996 toegenomen in Nederland. In de 
periode 1996-1999 werden 8 sterfgevallen geregistreerd t.o.v. van 0, 1, 0, 0 
and 2 sterfgevallen, respectievelijk, in de perioden 1976-1979, 1980-1983, 
1984-1987, 1988-1991 and 1992-1995 (Fig. 3. p.125). In 88% van de 
sterfgevallen betrof het kinderen jonger dan 3 maanden, hetgeen suggereert dat 
het aantal doden t.g.v. kinkhoest toeneemt in niet-geïmmuniseerde personen. 
Gandon et al. toonde aan in een mathematisch model dat sommige vaccins 
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selecteren voor meer virulente stammen. Een toename in frequentie van zulke 
stammen veroorzaakt vervolgens een toename in mortaliteit in naïeve personen. 
Ook de letaliteit (het aantal sterfgevallen / aantal ziekenhuisopnames) toonde 
een toename van 0.0000, 0.0022, 0,0000, 0.0000 and 0,0024 in de perioden 
1976-1979, 1980-1983, 1984-1987, 1988-1991 and 1992-1995, respectievelijk, 
naar 0.0046 in de periode 1996-1999 (Fig. 3. p.125). De toename in letaliteit 
was geassocieerd met een toename in frequentie van ptxP3 stammen, hetgeen 
suggereert dat ptxP3 stammen een ernstiger ziektebeeld veroorzaken door 
verhoogde pertussis toxine productie. Muisexperimenten tonen aan dat het 
aantal witte bloed cellen (leukocyten) in muizen, die geïnfecteerd zijn met een 
ptxP3 stam significant hoger waren t.o.v. muizen, die geïnfecteerd waren met 
een ptxP1 stam (hoofdstuk 6). In kinderen is de hoogte van leukocytose een 
maat voor de ernst van infectie en letaliteit. Een ziekte, die verloopt met 
ernstigere klinische symptomen, met name hoesten, heeft een hogere 
overdraagbaarheid van de bacterie tot gevolg. Verder wordt transmissie 
verhoogd door het betere koloniserende vermogen van ptxP3 stammen 
(hoofdstuk 6). Onze hypothese is dat een verhoogde pertussis toxine productie, 
gevonden in ptxP3 stammen (hoofdstuk 6), gunstig is voor transmissie door het 
veroorzaken van een ernstiger ziektebeeld en betere kolonisatie. Beide factoren 
kunnen mortaliteit beïnvloeden. 
 
Wij vonden een associatie tussen bepaalde prn allelen en allelen van andere 
polymorfe genen, b.v. tcfA3 was geassocieerd met prn3 en ptxP3 met prn2 
(hoofdstuk 3). Dit was onverwacht, omdat variatie in Prn is gebaseerd op 
recombinatie in repeterende eenheden DNA, hetgeen met een hoge frequentie 
gebeurt en reversibel is. Gupta et al. heeft aangetoond dat bacterie populaties 
zich opsplitsen in stammen met niet-overlappende antigene structuren, wanneer 
deze antigenen immunodominant zijn. De associatie tussen prn allelen en allelen 
van andere polymorfe genen geeft een sterke immuunselectie aan gericht tegen 
Prn, TcfA en andere nog niet bekende B. pertussis antigenen.   
Verschillende studies tonen aan dat Prn, TcfA en Ptx belangrijk zijn voor 
immuniteit. Sero-epidemiologische studies tonen een correlatie aan tussen de 
titer van anti-Prn antistoffen en bescherming tegen klinische symptomen. 
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Vaccinatie met een monocomponent pertussis toxoid vaccin induceert 
significante bescherming voor tenminste 2 jaar en verminderde de transmissie 
van B. pertussis in een populatie. Vaccinatie met TcfA verminderde significant de 
kolonisatie van trachea in muizen. Het feit dat polymorfe gebieden in Ptx en Prn 
B- en T-cel epitopen bevat, geeft aan dat deze gebieden belangrijk zijn voor de 
immuunrespons. Verder was variatie in Prn van invloed of de efficacy van een 
hele cel vaccin in muizen. Bescherming was het best tegen het vaccintype, Prn1 
en minder tegen de niet-vaccintypen Prn2 en Prn3. Wij vonden dat stammen 
met de niet-vaccintypen Prn en PtxS1 minder goed in staat waren om naïeve 
muizen te infecteren vergeleken met de vaccintype stam (hoofdstuk 5). Deze 
data geven aan dat vaccinatie de competitieve balans tussen stammen heeft 
verschoven, hetgeen heeft geleid tot een toename in frequentie van stammen, 
die minder goed kunnen overleven in niet immune personen. 
De volgende vraag is hoe pathogenen met polymorfe antigenen, zoals B. 
pertussis, beter bestreden kunnen worden. Mathematische modellering 
benadrukt dat het van belang is om geconserveerde antigenen te gebruiken, 
zelfs als deze minder immunogeen zijn. In dit proefschrift hebben wij een aantal 
geconserveerde antigenen beschreven, zoals BrkA, FHA, Fimbriae, OmpP, OmpQ 
en Vag8, die geschikt kunnen zijn voor toekomstige kinkhoestvaccins (hoofdstuk 
3). Vanwege hun rol in immuniteit tegen B. pertussis zijn de polymorfe 
antigenen TcfA en Prn potentiële vaccinkandidaten, vooral wanneer de 
immuunrespons wordt gericht naar geconserveerde epitopen. 
 
De data gepresenteerd in dit proefschrift geven een verklaring voor de 
wederopkomst van kinkhoest in Nederland en een beter begrip van de evolutie 
van pathogenen na de introductie van vaccinatie. Wij hebben aangetoond dat 
vaccinatie mogelijk heeft geresulteerd in de selectie van meer virulente 
stammen. Wij hopen dat deze kennis bijdraagt tot de ontwikkeling van betere 
kinkhoestvaccins. 
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al ik eens bellen?, dacht ik in de zomer van 1997, toen ik deze baan in de 
krant zag staan. Dat dit een goede gedachte was blijkt uit het tot stand 
komen van dit boekje. Een bijzonder moment om iedereen te bedanken, die 
hieraan meegewerkt heeft. 
Allereerst Frits, dank je voor het onder je hoede nemen van een dokter met 
onderzoeksambities. Ik bewonder je altijd aanwezige enthousiasme en enorme 
vasthoudendheid. Elk resultaat kon je positief beoordelen, bijzonder motiverend! 
Jan Verhoef wil ik hier graag bedanken voor zijn belangstelling voor het 
kinkhoestonderzoek en zijn bijdrage aan de mogelijkheid om dit project te 
kunnen voltooien. 
Dan kom ik nu bij alle labgenoten, die het LIO-leven tot een leuke tijd hebben 
gemaakt. Een aantal wil ik hier graag met naam noemen: 
Kees, je hebt mij de trucjes van het gelen gieten, het PCRen en cloneren 
bijgebracht. De vele discussies en de 1-persoons flowkast in S224 hebben ons 
bij het uitvoeren van de muisexperimenten wel dichter bij elkaar gebracht, vind 
je niet? Ik zal ons “wieltjes-contact” toch wel missen, hoor.  
Henk en Hans, bedankt voor het zo vlekkeloos uitvoeren van onze muisproeven. 
Arianne en Tamara, samen in het ijskoude water van het kanaal bij Stein, mijn 
eerste kwart triatlon. Ik zal het nooit vergeten!  
Sanne en Dimitri, mijn 2 stagaires, veel werk verzet, een leuke tijd gehad en ik 
heb ook zeker wat van jullie geleerd! Han, Audrey, Silke, Sandra en Hans, ieder 
waren jullie op jullie eigen bijzondere manier aanwezig op het LIO en leuke 
collega´s. De “Bob-avondjes” waren altijd zeer geslaagd. 
Ariënne, je bent erbij geweest vanaf de allereerste dag in Utrecht (op de 
straathoek bij Hans P.) tot de laatste dag, erg leuk dat je paranimf wil zijn. 
Als laatste wil ik mijn thuisfront bedanken. Mam en pap, op jullie steun, 
vertrouwen en belangstelling heb ik altjd kunnen rekenen. Jullie “avontuurlijke” 
dochter komt wel op haar plekje terecht, denk ik. Aimée, de “endless roads”, ik 
zal ze me blijven herinneren, een onvergetelijke ervaring aan de andere kant 
van de grote plas.  
En dan als allerlaatste: lieve Ruud. Eigenlijk hoef ik niets meer tegen je te 
zeggen. Ik hoop alleen maar dat ik er voor jou kan zijn, zoals jij er afgelopen 
jaren voor mij bent geweest. En nu weer een stapje richting het zuiden! 
Z
 
 Curriculum vitae 
 155
 
nge van Loo werd geboren op 21 januari 1972 in Maastricht, waar zij 
opgroeide en in 1990 het Gymnasium B diploma behaalde aan De Stedelijke 
Scholengemeenschap te Maastricht. Vervolgens ging zij geneeskunde studeren 
in Utrecht en behaalde haar propedeuse in 1991. Tijdens de daaropvolgende 
doctoraalstudie heeft zij o.a. stage gelopen bij de vakgroep Fysiologie en 
Sportgeneeskunde te Utrecht (Dr. Inge Huisveld) en bij het Laboratorium voor 
Medische Microbiologie te Lund (Dr. Åsa Ljungh) in Zweden. In 1995 behaalde 
zij het doctoraaldiploma en doorliep vervolgens de coschappen, waarbij het 
keuze-coschap werd gevolgd bij de afdelingen Medische Microbiologie en 
Infectieziekten van het Academisch Ziekenhuis Utrecht en het Wilhelmina 
Kinderziekenhuis. Zij behaalde het artsendiploma in 1997 en kon in ditzelfde 
jaar beginnen als assistent in opleiding bij het Eijkman-Winkler Instituut voor 
Medische Microbiologie van het Academisch Ziekenhuis Utrecht (Prof. Dr. Jan 
Verhoef). Dit promotieonderzoek is uitgevoerd o.l.v. Prof. Dr. Frits Mooi bij het 
Laboratorium voor Infectieziekten Onderzoek bij het Rijksinstituut voor 
Volksgezondheid en Milieu te Bilthoven en heeft geleid tot het schrijven van dit 
proefschrift. Zij zal haar loopbaan vervolgen op de afdeling Medische 
Microbiologie van het Elizabeth ziekenhuis te Tilburg, waar zij bij Dr. Marcel 
Peeters als arts-assistent de opleiding tot arts-microbioloog gaat volgen. 
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 Abbreviations 
 
Ac-Hly:  Adenylate cyclase hemolysin 
ACV:   Acellular vaccine 
BG:   Borduet Gengou 
BipA:  Bordetella intermediate phase protein 
bp:   basepair 
BrkA:  Bordetella resistance to killing 
Bvg:   Bordetella virulence genes 
CFU:   Colony forming units 
DTPP:  Diphtheria, tetanus, polio and pertussis 
dt (=ft):  DNA-type 
Fim:   Fimbriae 
FHA:   Filamentous hemagglutinin 
ft (=dt):  fingerprint type 
GD:   genotypic diversity 
Gen:   Gentamycin 
Kan:   Kanamycin 
ko:   knock-out 
MLEE:  Multi-locus enzyme electrophoresis 
MLST:  Multi-locus sequence typing 
OmpP/Q:  Outermembrane protein P/Q 
PFGE:  Pulse field gel electrophoresis 
Prn:   Pertactin 
Ptx(S1-S5)/(P): Pertussis toxin (subunits S1-S5)/(promoter) 
RF:   Relative Fitness 
RFLP:  Restriction fragment length polymorphism 
st:   serotype 
TcfA:   Tracheal colinization factor 
TCT:   Tracheal cytotoxin 
vag/vrg:  Virulence activated genes/virulence repressed genes 
WCV:  Whole cell vaccine 
wt:   wild-type 
  
   
 
  
